[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 245
1. Cavlan D, Bharwani N, Grossman A: Androgen- and estrogen-secreting adrenal cancers. Semin Oncol; 2010 Dec;37(6):638-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgen- and estrogen-secreting adrenal cancers.
  • Androgen-secreting adrenal cancers are extremely rare malignancies, accounting for only a tiny proportion of the total number of women presenting with signs of androgen excess.
  • Estrogen-secreting adrenal cancers are rarer still.
  • Understanding how these tumors work benefits from an appreciation of adrenal steroid biosynthesis, as it is said that secretion in cancers is an anarchic version of normal adrenal function.
  • Selection of patients in whom we should have a high suspicion of a malignancy is vital, so that biochemical investigation and imaging is deployed appropriately.
  • When an adrenal tumor is found to secrete androgens or estrogens to excess, it can be difficult to confirm that it is a cancer, as there is significant overlap in the secretory patterns and imaging appearances of benign and malignant disease.
  • The most reliable indicator of malignancy in these tumors remains the presence of metastases.
  • [MeSH-major] Adrenal Gland Neoplasms / secretion. Androgens / secretion. Estrogens / secretion
  • [MeSH-minor] Adrenalectomy. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / secretion. Adrenocortical Carcinoma / therapy. Adult. Algorithms. Antineoplastic Agents, Hormonal / therapeutic use. Child. Diagnostic Imaging / methods. Female. Humans. Mitotane / therapeutic use. Prognosis. Virilism / etiology

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21167382.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Antineoplastic Agents, Hormonal; 0 / Estrogens; 78E4J5IB5J / Mitotane
  •  go-up   go-down


2. Figueiredo BC, Sandrini R, Zambetti GP, Pereira RM, Cheng C, Liu W, Lacerda L, Pianovski MA, Michalkiewicz E, Jenkins J, Rodriguez-Galindo C, Mastellaro MJ, Vianna S, Watanabe F, Sandrini F, Arram SB, Boffetta P, Ribeiro RC: Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet; 2006 Jan;43(1):91-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: An inherited germline P53 mutation has been identified in cases of childhood adrenocortical carcinoma (ACT), a neoplasm with a high incidence in southern Brazil.
  • CONCLUSIONS: The TP53 R337H mutation dramatically increases predisposition to childhood ACT but not to other cancers, and explains the increased frequency of ACT observed in this geographic region.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jun;82(12):1932-7 [10864200.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5 [11481490.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4970-3 [11600572.001]
  • [Cites] Nat Struct Biol. 2002 Jan;9(1):12-6 [11753428.001]
  • [Cites] Pediatrics. 2003 Dec;112(6 Pt 1):1248-55 [14654593.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):838-45 [14990639.001]
  • [Cites] J Biol Chem. 2005 Jun 24;280(25):24245-51 [15851479.001]
  • [Cites] Cancer Res. 1988 Sep 15;48(18):5358-62 [3409256.001]
  • [Cites] Science. 1990 Nov 30;250(4985):1233-8 [1978757.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1298-304 [8118819.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):1-13 [9006316.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2027-31 [9215267.001]
  • [Cites] Genet Epidemiol. 1999;16(1):15-39 [9915565.001]
  • [Cites] J Med Genet. 2004 May;41(5):354-9 [15121773.001]
  • (PMID = 16033918.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / CA-71907
  • [Publication-type] Letter; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2564508
  •  go-up   go-down


3. Abiraterone acetate. Drugs R D; 2010;10(4):261-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abiraterone acetate (CB 7630; CB7630; JNJ-212082), the 3β-acetate prodrug of abiraterone, is structurally related to ketoconazole and is being developed by Cougar Biotechnology as a hormonal therapy for advanced prostate and breast cancers.
  • As a selective inhibitor of adrenal androgens, it is thought to be a safer product than existing second-line hormonal therapies.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Androstadienes / pharmacology. Androstadienes / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Drugs, Investigational / therapeutic use. Neoplasms / drug therapy. Prodrugs / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Steroid Biochem Mol Biol. 1994 Sep;50(5-6):267-73 [7918112.001]
  • (PMID = 21171672.001).
  • [ISSN] 1179-6901
  • [Journal-full-title] Drugs in R&D
  • [ISO-abbreviation] Drugs R D
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Androstadienes; 0 / Antineoplastic Agents, Hormonal; 0 / Drugs, Investigational; 0 / Prodrugs; EM5OCB9YJ6 / Abiraterone Acetate
  • [Other-IDs] NLM/ PMC3586139
  •  go-up   go-down


Advertisement
4. Ozben B, Papila N, Tanrikulu MA, Bayalan F, Fak AS, Oktay A: Inferior vena caval tumor thrombus extending into the right atrium in a patient with pancreatic cancer. J Thromb Thrombolysis; 2007 Dec;24(3):317-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inferior vena caval tumor thrombus extending into the right atrium in a patient with pancreatic cancer.
  • Venous thromboembolism is a common complication in patients with cancer and an important cause of morbidity and mortality.
  • Idiopathic thrombosis, migratory or recurrent thrombophlebitis may be the first manifestation of an occult malignancy.
  • While deep venous thrombosis and pulmonary embolism are the most common thrombotic conditions in patients with malignant disease, tumor thrombus may be seen in inferior vena cava, mainly in patients with renal cell carcinoma, hepatocellular carcinoma, testicular tumors or adrenal carcinoma.
  • Although pancreatic cancer is one of the cancers that are most strongly associated with thrombotic complications along with cancers of ovary and brain, there has been no report about presence of thrombus in the inferior vena cava in pancreatic cancer.
  • We report a female patient with pancreatic cancer associated with tumor thrombus extending from the inferior vena cava to the right atrium.
  • [MeSH-major] Pancreatic Neoplasms / complications. Vena Cava, Inferior / pathology. Venous Thromboembolism / etiology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Vasc Surg. 2006 Mar;20(2):223-7 [16550482.001]
  • [Cites] Cancer. 1954 May;7(3):462-503 [13160935.001]
  • [Cites] Gan To Kagaku Ryoho. 2006 Nov;33(11):1653-6 [17108735.001]
  • [Cites] J Urol. 1987 Jan;137(1):21-4 [3795361.001]
  • [Cites] Surgery. 1991 Feb;109 (2):214-9 [1846985.001]
  • [Cites] Arch Esp Urol. 2003 Jun;56(5):485-9 [12918305.001]
  • [Cites] N Engl J Med. 1996 Sep 19;335(12):865-75 [8778606.001]
  • [Cites] J Med Invest. 2000 Aug;47(3-4):155-60 [11019497.001]
  • [Cites] JAMA. 1961 Aug 26;177:542-5 [13762005.001]
  • [Cites] Urol Oncol. 2003 Sep-Oct;21(5):327-33 [14670538.001]
  • [Cites] Semin Oncol. 1990 Apr;17(2):147-59 [2183357.001]
  • [Cites] Circulation. 2003 Jun 17;107(23 Suppl 1):I17-21 [12814981.001]
  • [Cites] Cancer Invest. 2001;19(1):65-75 [11291558.001]
  • [Cites] Thromb Haemost. 2002 Jun;87(6):1076-7 [12083490.001]
  • [Cites] Medicine (Baltimore). 1999 Sep;78(5):285-91 [10499070.001]
  • [Cites] Ann Thorac Surg. 1997 Jun;63(6):1592-600 [9205155.001]
  • [Cites] Chin Med J (Engl). 2006 Nov 20;119(22):1934-6 [17134595.001]
  • [Cites] N Engl J Med. 1996 Mar 14;334(11):677-81 [8594425.001]
  • [Cites] J Surg Oncol. 1995 Jun;59(2):94-100 [7776659.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):212-6 [15783033.001]
  • [Cites] Ann Surg. 1989 Sep;210(3):387-92; discussion 392-4 [2774709.001]
  • [Cites] Urology. 1995 Dec;46(6):883-7 [7502438.001]
  • [Cites] Semin Thromb Hemost. 1999;25(2):137-45 [10357081.001]
  • [Cites] J Am Coll Surg. 2002 Dec;195(6):892-4 [12495323.001]
  • [Cites] Eur Urol. 1992;21(1):82-4 [1318844.001]
  • [Cites] Hepatogastroenterology. 1997 May-Jun;44(15):824-5 [9222699.001]
  • [Cites] Echocardiography. 2002 Feb;19(2):149-51 [11926979.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1374-7 [12352396.001]
  • [Cites] Prog Urol. 2002 Sep;12(4):668-71 [12463131.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] Hepatogastroenterology. 1994 Apr;41(2):154-7 [8056404.001]
  • [Cites] Int J Urol. 2006 Aug;13(8):1144-6 [16903951.001]
  • [Cites] Abdom Imaging. 1994 Jul-Aug;19(4):313-6 [8075552.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):273-9 [8604907.001]
  • [Cites] Medicine (Baltimore). 1977 Jan;56(1):1-37 [834136.001]
  • [Cites] Pancreas. 2004 Apr;28(3):301-4 [15084976.001]
  • [Cites] Int J Urol. 2005 May;12(5):513-5 [15948757.001]
  • [Cites] Teratog Carcinog Mutagen. 2001;21(1):7-25 [11135318.001]
  • [Cites] J Vasc Surg. 2001 Apr;33(4):789-96 [11296333.001]
  • [Cites] Circulation. 1997 Oct 21;96(8):2729-30 [9355916.001]
  • [Cites] Arch Intern Med. 2000 Mar 27;160(6):809-15 [10737280.001]
  • [Cites] Ann Thorac Surg. 2001 Feb;71(2):733-4 [11235750.001]
  • [Cites] J Urol. 1984 Dec;132(6):1097-100 [6502795.001]
  • [Cites] Urology. 2004 Feb;63(2):380-2 [14972500.001]
  • (PMID = 17483876.001).
  • [ISSN] 0929-5305
  • [Journal-full-title] Journal of thrombosis and thrombolysis
  • [ISO-abbreviation] J. Thromb. Thrombolysis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


5. Chen ML, Xu PZ, Peng XD, Chen WS, Guzman G, Yang X, Di Cristofano A, Pandolfi PP, Hay N: The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev; 2006 Jun 15;20(12):1569-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice.
  • The tumor suppressor PTEN is frequently inactivated in human cancers.
  • Here we showed that the deficiency of Akt1 is sufficient to dramatically inhibit tumor development in Pten+/- mice.
  • Akt1 deficiency had a profound effect on endometrium and prostate neoplasia, two types of human cancer, in which PTEN is frequently mutated, and also affected thyroid and adrenal medulla tumors and intestinal polyps.
  • Even haplodeficiency of Akt1 was sufficient to markedly attenuate the development of high-grade prostate intraepithelial neoplasia (PIN) and endometrial carcinoma.
  • These results have significant implications for cancer therapy.


6. Yang JY, Yang MQ, Luo Z, Ma Y, Li J, Deng Y, Huang X: A hybrid machine learning-based method for classifying the Cushing's Syndrome with comorbid adrenocortical lesions. BMC Genomics; 2008;9 Suppl 1:S23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The prognosis for many cancers could be improved dramatically if they could be detected while still at the microscopic disease stage.
  • It follows from a comprehensive statistical analysis that a number of antigens such as hTERT, PCNA and Ki-67 can be considered as cancer markers, while another set of antigens such as P27KIP1 and FHIT are possible markers for normal tissue.
  • Because more than one marker must be considered to obtain a classification of cancer or no cancer, and if cancer, to classify it as malignant, borderline, or benign, we must develop an intelligent decision system that can fullfill such an unmet medical need.
  • We provided statistical evidence that higher expression levels of hTERT, PCNA and Ki-67 etc. are associated with a higher risk that the tumors are malignant or borderline as opposed to benign.
  • While no significant difference was found between cell-arrest antigens such as P27KIP1 for malignant, borderline, and benign tumors, there was a significant difference between expression levels of such antigens in normal adrenal medulla samples and in adrenomedullary tumors.
  • This research has many potential applications; it might provide an alternative diagnostic tool and a better understanding of the mechanisms involved in malignant transformation as well as information that is useful for treatment planning and cancer prevention.
  • [MeSH-major] Adrenal Cortex Neoplasms / classification. Algorithms. Artificial Intelligence. Biomarkers, Tumor / metabolism. Cushing Syndrome / classification


7. Zografos GN, Vasiliadis G, Farfaras AN, Aggeli C, Digalakis M: Laparoscopic surgery for malignant adrenal tumors. JSLS; 2009 Apr-Jun;13(2):196-202
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic surgery for malignant adrenal tumors.
  • Advances in imaging have improved early detection of primary and metastatic adrenal tumors.
  • The laparoscopic approach, the gold standard for benign adrenal diseases, is controversial for malignant adrenal tumors.
  • A prospective randomized study of the role of laparoscopic surgery in adrenal cancer is not feasible because of the rarity of the disease.
  • A review of the literature demonstrates the safety and efficacy of laparoscopic adrenalectomy for solitary adrenal tumors.
  • In primary adrenal malignancies, the laparoscopic approach should be considered cautiously, only when it can achieve complete tumor resection with an intact adrenal capsule.
  • Conversion to an open procedure should be an early decision, prior to tumor morcellation or fracture of the tumor capsule.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37 [16551738.001]
  • [Cites] Hormones (Athens). 2006 Jan-Mar;5(1):52-6 [16728385.001]
  • [Cites] J Surg Oncol. 2006 Aug 1;94(2):128-31 [16847903.001]
  • [Cites] Clin Nucl Med. 2006 Dec;31(12):822-5 [17117086.001]
  • [Cites] Eur J Endocrinol. 2007 Apr;156(4):483-7 [17389464.001]
  • [Cites] J Endocrinol Invest. 2007 Mar;30(3):200-4 [17505152.001]
  • [Cites] Surg Endosc. 2007 Aug;21(8):1373-6 [17356945.001]
  • [Cites] JSLS. 2007 Apr-Jun;11(2):261-5 [17761094.001]
  • [Cites] JSLS. 2007 Oct-Dec;11(4):487-92 [18237516.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2008 Feb;18(1):42-6 [18266573.001]
  • [Cites] Surg Clin North Am. 2000 Oct;80(5):1427-41 [11059712.001]
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] Surgery. 2001 Dec;130(6):1072-7 [11742341.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2001 Dec;11(6):409-13 [11814133.001]
  • [Cites] Arch Surg. 2002 Aug;137(8):948-51; discussion 952-3 [12146996.001]
  • [Cites] World J Surg. 2002 Aug;26(8):1043-7 [12045859.001]
  • [Cites] Ann Chir. 2002 Sep;127(7):512-9 [12404845.001]
  • [Cites] Biomed Pharmacother. 2002;56 Suppl 1:132s-138s [12487269.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Apr;13(2):106-10 [12709616.001]
  • [Cites] Surg Oncol. 2003 Aug;12(2):105-23 [12946482.001]
  • [Cites] Ann Surg Oncol. 2003 Dec;10(10):1191-6 [14654476.001]
  • [Cites] Minerva Chir. 2004 Feb;59(1):1-5 [15111826.001]
  • [Cites] Surg Clin North Am. 2004 Jun;84(3):755-74 [15145233.001]
  • [Cites] Am J Surg. 2004 Jun;187(6):705-12 [15191862.001]
  • [Cites] Am Surg. 2004 Aug;70(8):668-74 [15328798.001]
  • [Cites] N Engl J Med. 1984 Nov 15;311(20):1298-303 [6149463.001]
  • [Cites] J Surg Oncol. 1992 Aug;50(4):258-62 [1640712.001]
  • [Cites] N Engl J Med. 1992 Oct 1;327(14):1033 [1387700.001]
  • [Cites] J Endocrinol Invest. 1992 Oct;15(9):631-42 [1479146.001]
  • [Cites] J Endocrinol Invest. 1992 Oct;15(9):643-9 [1479147.001]
  • [Cites] Gynecol Oncol. 1993 Jul;50(1):15-9 [8349158.001]
  • [Cites] Intern Med. 1993 Oct;32(10):789-94 [8012074.001]
  • [Cites] J Surg Oncol. 1995 Mar;58(3):149-54 [7898109.001]
  • [Cites] Eur J Nucl Med. 1995 Apr;22(4):315-21 [7607261.001]
  • [Cites] Am J Hypertens. 1997 Apr;10(4 Pt 1):479-81 [9128218.001]
  • [Cites] J Clin Endocrinol Metab. 1997 May;82(5):1317-24 [9141510.001]
  • [Cites] Arch Surg. 1997 Aug;132(8):914-9 [9267279.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):238-46; discussion 246-7 [9339930.001]
  • [Cites] J Urol. 1997 Dec;158(6):2227 [9366350.001]
  • [Cites] Cancer. 1998 Jan 15;82(2):389-94 [9445197.001]
  • [Cites] Urology. 1998 Jun;51(6):920-5 [9609627.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):765-89 [9735133.001]
  • [Cites] Cytokine. 1998 Sep;10(9):720-8 [9770334.001]
  • [Cites] Eur J Cancer. 1998 Oct;34(11):1721-4 [9893659.001]
  • [Cites] Semin Surg Oncol. 1999 Jun;16(4):293-306 [10332775.001]
  • [Cites] BJU Int. 2004 Nov;94(7):1026-9 [15541121.001]
  • [Cites] Lancet Oncol. 2004 Dec;5(12):718-26 [15581542.001]
  • [Cites] J Urol. 2005 Feb;173(2):519-25 [15643237.001]
  • [Cites] World J Surg. 2004 Nov;28(11):1176-9 [15490056.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Mar;5(2):139-48 [15810878.001]
  • [Cites] Am J Surg. 2005 Apr;189(4):405-11 [15820450.001]
  • [Cites] Eur J Cardiothorac Surg. 2005 May;27(5):753-6 [15848309.001]
  • [Cites] Horm Metab Res. 2005 Dec;37(12):717-21 [16372223.001]
  • [Cites] World J Surg. 2006 May;30(5):893-8 [16680605.001]
  • [Cites] Semin Nucl Med. 2006 Jul;36(3):228-47 [16762613.001]
  • (PMID = 19660215.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 63
  • [Other-IDs] NLM/ PMC3015945
  •  go-up   go-down


8. Wakshlag JJ, McNeill CJ, Antonyak MA, Boehm JE, Fuji R, Balkman CE, Zgola M, Cerione RA, Page RL: Expression and activity of transglutaminase II in spontaneous tumours of dogs and cats. J Comp Pathol; 2006 Feb-Apr;134(2-3):202-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bladder, liver and adrenal gland exhibited prominent expression of TGase II while other tissues, including mammary gland, displayed limited expression and activity.
  • Thus, TGase II was significantly expressed in mammary cancers from dogs and cats and immunoreactivity of TGase II was similar to that reported in humans beings.
  • [MeSH-major] Carcinoma / veterinary. GTP-Binding Proteins / metabolism. Mammary Glands, Animal / enzymology. Mammary Neoplasms, Animal / enzymology. Transglutaminases / metabolism
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Blotting, Western / veterinary. Cats. Cell Line, Tumor. Cell Survival / drug effects. Dogs. Doxorubicin / pharmacology. Drug Screening Assays, Antitumor / veterinary. Female. Fluorescent Antibody Technique, Indirect / veterinary. Hyperplasia / enzymology. Hyperplasia / pathology. Hyperplasia / veterinary. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16615935.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM61762
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; EC 2.3.2.- / transglutaminase 2; EC 2.3.2.13 / Transglutaminases; EC 3.6.1.- / GTP-Binding Proteins
  •  go-up   go-down


9. van Duursen MB, Nijmeijer SM, Ruchirawat S, van den Berg M: Chemopreventive actions by enterolactone and 13 VIOXX-related lactone derivatives in H295R human adrenocortical carcinoma cells. Toxicol Lett; 2010 Feb 15;192(3):271-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytochrome P450c17 (CYP17) has been linked to various hormone-related diseases, including breast cancer, thus being a potential target for cancer chemoprevention.
  • We conclude that the proposed cancer chemopreventive actions of ENL are not mediated through interaction with CYP17 or cell cycle status.
  • Of the VIOXX-related lactone derivatives, CRI-7 could prove useful in the prevention of hormone-dependent cancers, such as breast cancer, since in vitro it shows low cytotoxicity, it is a potent inhibitor of CYP17 activity and strong inducer of cell cycle arrest.
  • [MeSH-major] 4-Butyrolactone / analogs & derivatives. Adrenal Cortex Neoplasms / enzymology. Adrenocortical Carcinoma / enzymology. Lactones / pharmacology. Lignans / pharmacology. Phytoestrogens / pharmacology. Steroid 17-alpha-Hydroxylase / drug effects. Sulfones / pharmacology
  • [MeSH-minor] Cell Cycle / drug effects. Cell Line, Tumor. Enzyme Induction / drug effects. Flavonoids / pharmacology. Gene Expression / drug effects. Humans. Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors. Neoplasms, Hormone-Dependent / prevention & control. Protein Processing, Post-Translational / drug effects. Structure-Activity Relationship

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BUTYROLACTONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19913079.001).
  • [ISSN] 1879-3169
  • [Journal-full-title] Toxicology letters
  • [ISO-abbreviation] Toxicol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one; 0 / Flavonoids; 0 / Lactones; 0 / Lignans; 0 / Phytoestrogens; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib; EC 1.14.99.9 / Steroid 17-alpha-Hydroxylase; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; OL659KIY4X / 4-Butyrolactone; X01E7E1D6H / 2,3-bis(3'-hydroxybenzyl)butyrolactone
  •  go-up   go-down


10. Thiboutot DM, Harper JC, O'Connell K, Rich P, Sondheimer SJ: Improving outcomes through collaboration. Cutis; 2008 Jan;81(1 Suppl):26-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although PCOS is often the source of the problem, it is important to rule out a testosterone-producing tumor or an adrenal tumor.
  • It was determined, however, that the perception that OCs cause cervical and breast cancer persists among some dermatologists.
  • Even in women with a family history of breast cancer, OCs do not increase the risk.
  • Nor is cervical cancer related to OC use; rather, it results from human papillomavirus.
  • Thus, patients should be assured that OCs will not increase their risk for either of these cancers.
  • [MeSH-minor] Acne Vulgaris / drug therapy. Acne Vulgaris / epidemiology. Acne Vulgaris / etiology. Affect / drug effects. Female. Genital Diseases, Female / diagnosis. Humans. Hyperandrogenism / complications. Hyperandrogenism / drug therapy. Libido / drug effects. Patient Education as Topic. Polycystic Ovary Syndrome / complications. Polycystic Ovary Syndrome / drug therapy. Sex Factors. Weight Gain / drug effects

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18340677.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptives, Oral
  •  go-up   go-down


11. Kumanov P, Nandipati KC, Tomova A, Robeva R, Agarwal A: Significance of inhibin in reproductive pathophysiology and current clinical applications. Reprod Biomed Online; 2005 Jun;10(6):786-812
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inhibin concentrations are elevated in patients with granulosa cell tumours and in post-menopausal women with mucinous ovarian cancers.
  • Immunoreactivity against the inhibin alpha-subunit was identified in all cases of adrenal cortical adenoma and carcinoma, and levels are suppressed in the malignant prostate disease.
  • [MeSH-minor] Activins / chemistry. Activins / metabolism. Adult. Age Factors. Chromosomes, Human, Y. Exocrine Glands / metabolism. Female. Fertilization in Vitro / methods. Follistatin / chemistry. Follistatin / metabolism. Humans. Infant, Newborn. Male. Menstrual Cycle / physiology. Ovarian Neoplasms / blood. Polycystic Ovary Syndrome / physiopathology. Pregnancy. Sequence Deletion. alpha-Macroglobulins / chemistry. alpha-Macroglobulins / metabolism

  • MedlinePlus Health Information. consumer health - Male Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15970011.001).
  • [ISSN] 1472-6483
  • [Journal-full-title] Reproductive biomedicine online
  • [ISO-abbreviation] Reprod. Biomed. Online
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Follistatin; 0 / alpha-Macroglobulins; 104625-48-1 / Activins; 57285-09-3 / Inhibins
  • [Number-of-references] 114
  •  go-up   go-down


12. El Bahri DM, Meddeb N, Sellami S: [Rheumatoid arthritis: current status of therapy]. Tunis Med; 2007 Jan;85(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Actualités thérapeutiques de la polyarthrite rhumatoïde.
  • Recent advances in the field of immunopathology of RA have oriented treatment targeting the pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF alpha), interleukin (IL) and IL6.
  • However, before any biotherapy prescription especially of anti-TNF-alpha, an initial screening should be achieved to exclude patients with history of untreated tuberculosis, solid cancers, malignant hemopathies or demyelinating disorders.
  • [MeSH-minor] Adalimumab. Adrenal Cortex Hormones / administration & dosage. Adrenal Cortex Hormones / therapeutic use. Adult. Animals. Anti-Inflammatory Agents / administration & dosage. Anti-Inflammatory Agents / adverse effects. Anti-Inflammatory Agents / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antirheumatic Agents / administration & dosage. Antirheumatic Agents / adverse effects. Antirheumatic Agents / therapeutic use. Biological Therapy / adverse effects. Biological Therapy / methods. Controlled Clinical Trials as Topic. Disease Models, Animal. Etanercept. Follow-Up Studies. Humans. Immunoglobulin G / administration & dosage. Immunoglobulin G / adverse effects. Immunoglobulin G / therapeutic use. Infliximab. Interleukin 1 Receptor Antagonist Protein / administration & dosage. Interleukin 1 Receptor Antagonist Protein / adverse effects. Interleukin 1 Receptor Antagonist Protein / therapeutic use. Interleukin-1 / antagonists & inhibitors. Receptors, Tumor Necrosis Factor / administration & dosage. Receptors, Tumor Necrosis Factor / therapeutic use. Risk Assessment. Spondylarthropathies / drug therapy. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • Hazardous Substances Data Bank. Infliximab .
  • Hazardous Substances Data Bank. Etanercept .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17424701.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anti-Inflammatory Agents; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antirheumatic Agents; 0 / Immunoglobulin G; 0 / Interleukin 1 Receptor Antagonist Protein; 0 / Interleukin-1; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab; FYS6T7F842 / Adalimumab; OP401G7OJC / Etanercept
  • [Number-of-references] 66
  •  go-up   go-down


13. Selcer KW, Difrancesca HM, Chandra AB, Li PK: Immunohistochemical analysis of steroid sulfatase in human tissues. J Steroid Biochem Mol Biol; 2007 Jun-Jul;105(1-5):115-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This enzyme is best known for its role in estrogen production via the fetal adrenal-placental pathway during pregnancy; however, it also has important functions in other physiological and pathological steroid pathways.
  • The objective of this study was to examine the distribution of steroid sulfatase in normal human tissues and in breast cancers using immunohistochemistry, employing a newly developed steroid sulfatase antibody.
  • The antiserum also crossreacted with single protein bands in Western blots of microsomes from two human breast cancer cell lines (MDA-MB-231 and MCF-7) and from rat liver; however, there were some size differences in the immunoreactive bands among tissues.
  • ER+/PR+ breast cancers also showed relatively strong levels of steroid sulfatase immunoreactivity.
  • Normal human breast showed moderate levels of steroid sulfatase immunoreactivity, while ER-/PR- breast cancer showed weak immunoreactivity.
  • This confirms previous reports that steroid sulfatase is higher in hormone-dependent breast cancers.
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Humans. Immunohistochemistry. Tissue Array Analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17604157.001).
  • [ISSN] 0960-0760
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.6.2 / Steryl-Sulfatase
  •  go-up   go-down


14. Jurczyńska J, Zieleniewski W, Stepień H, Komorowski J: Angiogenic and anti-angiogenic factors in adrenal tumours. Endokrynol Pol; 2006 Nov-Dec;57(6):633-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenic and anti-angiogenic factors in adrenal tumours.
  • It appears that neoangiogenesis is an important factor in tumour invasion and the formation of metastases in several human cancers, and studies on pro-angiogenic and antiangiogenic factors are therefore of considerable interest to researchers.
  • In this review we present pro-angiogenic and anti-angiogenic factors and other growth factors and their role in the formation of new blood vessels in adrenal tumours.
  • Assessment of the angiogenic status of adrenal tumours and their vascular pattern may be useful for discriminating benign from malignant lesions and knowledge of their angiogenesis may be essential to the drawing up of promising treatment strategies for patients with malignant tumours.
  • [MeSH-major] Adrenal Gland Neoplasms / physiopathology. Adrenal Glands / blood supply. Angiogenesis Inducing Agents / metabolism. Angiogenesis Inhibitors / metabolism

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17253437.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Angiogenesis Inhibitors
  • [Number-of-references] 69
  •  go-up   go-down


15. Baston E, Leroux FR: Inhibitors of steroidal cytochrome p450 enzymes as targets for drug development. Recent Pat Anticancer Drug Discov; 2007 Jan;2(1):31-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It catalyzes the last step of the androgen biosynthesis in the testes and adrenal glands and produces androstenedione and dehydroepiandrosterone from progesterone and pregnenolone.
  • Estrogens stimulate tumor growth in hormone dependent breast cancer.
  • In addition, about 80 percent of prostate cancers are androgen dependent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18221052.001).
  • [ISSN] 1574-8928
  • [Journal-full-title] Recent patents on anti-cancer drug discovery
  • [ISO-abbreviation] Recent Pat Anticancer Drug Discov
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Aromatase Inhibitors; 0 / Cytochrome P-450 Enzyme Inhibitors; 0 / Enzyme Inhibitors; EC 1.14.15.4 / Cytochrome P-450 CYP11B2; EC 1.14.99.9 / Steroid 17-alpha-Hydroxylase
  • [Number-of-references] 105
  •  go-up   go-down


16. Pawlikowski M, Winczyk K, Sledź B: Immunohistochemical detection of angiotensin receptors AT1 and AT2 in adrenal tumors. Folia Histochem Cytobiol; 2008;46(1):51-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical detection of angiotensin receptors AT1 and AT2 in adrenal tumors.
  • Angiotensin II is well known to affect the adrenal cell growth and function.
  • Angiotensin receptors AT1 and AT2 were found to be present in the normal adrenal gland.
  • However, the data on the expression of the angiotensin receptors in the adrenal tumors are very scarce.
  • To overcome this gap, the paraffin sections of the adrenal cortical tumors and of pheochromocytomas from the archival material were immunostained with antibodies raised against AT1 (sc-1173) and AT2 (sc-9040) receptor proteins.
  • In hyperplasia of the adrenal cortex and in benign adrenocortical adenomas, both functioning and non-functioning, the AT1 immunostaining was present mainly in the cell membranes.
  • In the adrenal cancer, as well as in pheochromocytomas, neither cell membranes nor cell nuclei were immunostained with anti-AT1 antibody.
  • Our data indicates that the expression of AT1 receptors is altered in adrenal cancer and in pheochromocytomas.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18296263.001).
  • [ISSN] 1897-5631
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Receptor, Angiotensin, Type 1; 0 / Receptor, Angiotensin, Type 2; 4964P6T9RB / Aldosterone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


17. Pittavini L, De Gaetano A, Solano G, Losito A: Resistant arterial hypertension: association with syncronous kidney cancer and adrenal adenoma. J Nephrol; 2010 Sep-Oct;23(5):614-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistant arterial hypertension: association with syncronous kidney cancer and adrenal adenoma.
  • The coexistence of renal cancer and adrenal adenoma is rare.
  • We report the case of a 60-year-old patient with synchronous hypernephroma and adrenal adenoma.
  • This suggests that the coexistence of kidney cancer and adrenal adenoma may be a curable cause of resistant hypertension.
  • [MeSH-major] Adenoma / complications. Adrenal Gland Neoplasms / complications. Carcinoma, Renal Cell / complications. Hypertension / etiology. Kidney Neoplasms / complications. Neoplasms, Multiple Primary / complications


18. Degraff DJ, Aguiar AA, Sikes RA: Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions. Am J Transl Res; 2009 Jan 20;1(2):115-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.
  • Accumulating evidence indicates that alterations in the IGF axis contribute to the development of chemo- and radio-resistant, advanced-stage cancers.
  • New evidence indicates that the IGFBPs, irrespective of ligand interactions, correlate with the development and metastatic behavior of several cancers.
  • Increased expression of insulin-like growth factor binding protein 2 (IGFBP-2) is found in advanced cancers of the ovary, breast, stomach, adrenal gland, bladder, CNS, and prostate.
  • Further, IGFBP-2 seemingly has ligand-independent effects that participate in the development and dissemination of advanced cancer cells.
  • As such, IGFBP-2 can assist in the development of the lethal phenotype for some cancers.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bull N Y Acad Med. 1963 Nov;39:752-7 [14057738.001]
  • [Cites] J R Coll Surg Edinb. 1959 Apr;4(3):191-8 [13655261.001]
  • [Cites] J Natl Cancer Inst. 1954 Aug;15(1):1-25 [13233864.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Oct 5;263(3):786-9 [10512758.001]
  • [Cites] Breast Cancer Res Treat. 1999 Jul;56(1):1-10 [10517338.001]
  • [Cites] Mol Cell Endocrinol. 1998 Mar 16;138(1-2):151-61 [9685224.001]
  • [Cites] J Biol Chem. 1999 Mar 12;274(11):6935-45 [10066747.001]
  • [Cites] J Clin Invest. 1997 Nov 15;100(10):2596-605 [9366575.001]
  • [Cites] Endocrinology. 1997 Oct;138(10):4181-90 [9322928.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3783-92 [8855838.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jul;81(7):2653-62 [8675593.001]
  • [Cites] Biochim Biophys Acta. 1996 Aug 21;1313(1):79-88 [8781553.001]
  • [Cites] Int J Urol. 1996 Jan;3(1):39-46 [8646598.001]
  • [Cites] Mol Endocrinol. 1995 Jul;9(7):902-12 [7476972.001]
  • [Cites] Endocrinology. 1995 Dec;136(12):5485-92 [7588299.001]
  • [Cites] Eur J Endocrinol. 1996 Apr;134(4):474-80 [8640300.001]
  • [Cites] Prog Growth Factor Res. 1995;6(2-4):357-66 [8817679.001]
  • [Cites] J Biol Chem. 1995 Sep 1;270(35):20424-31 [7544787.001]
  • [Cites] Endocrinology. 1995 Apr;136(4):1374-80 [7534697.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Mar;80(3):987-93 [7533776.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3732-7 [7518344.001]
  • [Cites] Endocrinology. 1995 Oct;136(10):4168-73 [7545099.001]
  • [Cites] Endocrinology. 1995 Apr;136(4):1403-10 [7534698.001]
  • [Cites] Prostate. 1995 Feb;26(2):72-9 [7531847.001]
  • [Cites] Endocrinology. 1995 Sep;136(9):4049-55 [7544275.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Nov;79(5):1410-5 [7525636.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6563-70 [7527300.001]
  • [Cites] Int J Cancer. 1994 May 15;57(4):491-7 [7514152.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Mar;78(3):778-83 [7510307.001]
  • [Cites] Endocrinology. 1994 Jan;134(1):126-32 [7506203.001]
  • [Cites] Mol Cell Endocrinol. 1994 Mar;99(2):211-20 [8206329.001]
  • [Cites] J Cell Physiol. 1993 Jun;155(3):556-67 [7684042.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Apr;76(4):1031-5 [7682560.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Jul;77(1):229-33 [7686915.001]
  • [Cites] J Biol Chem. 1993 Dec 15;268(35):26045-8 [7504671.001]
  • [Cites] Endocrinology. 1993 Mar;132(3):1176-83 [7679972.001]
  • [Cites] Endocrinology. 1993 Sep;133(3):1462-5 [7689959.001]
  • [Cites] J Cell Biol. 1993 May;121(3):679-87 [7683690.001]
  • [Cites] J Biol Chem. 1992 Jun 25;267(18):12692-9 [1377672.001]
  • [Cites] J Biol Chem. 1992 Nov 5;267(31):22467-72 [1385400.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Oct;75(4):1046-53 [1383255.001]
  • [Cites] J Biol Chem. 1992 Jun 15;267(17):11949-56 [1376315.001]
  • [Cites] J Biol Chem. 1992 Oct 15;267(29):21033-7 [1328218.001]
  • [Cites] Breast Cancer Res Treat. 1992;22(1):39-45 [1421423.001]
  • [Cites] Cell Growth Differ. 1991 Sep;2(9):457-64 [1661135.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Aug 30;179(1):378-85 [1652955.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1149-56 [16729015.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24588-601 [16793770.001]
  • [Cites] J Mol Endocrinol. 2006 Aug;37(1):13-23 [16901920.001]
  • [Cites] Biochim Biophys Acta. 2006 Aug;1766(1):1-22 [16844299.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1529-35 [16884361.001]
  • [Cites] Growth Horm IGF Res. 2006 Jun;16(3):202-10 [16844395.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6570-8 [16818629.001]
  • [Cites] Int J Oncol. 2006 Jul;29(1):193-200 [16773200.001]
  • [Cites] Genome Res. 2006 Jun;16(6):693-701 [16741161.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2002 Sep;16(3):433-47 [12464227.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1361-8 [12433712.001]
  • [Cites] J Endocrinol. 2002 Oct;175(1):19-31 [12379487.001]
  • [Cites] Endocrinology. 2002 Oct;143(10):3897-904 [12239101.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):705-12 [12163322.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1099-106 [12122101.001]
  • [Cites] Prostate. 2002 Aug 1;52(3):173-82 [12111694.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 3;94(13):972-80 [12096082.001]
  • [Cites] Endocrinology. 2002 Jul;143(7):2693-9 [12072403.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):389-96 [12044015.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10489-97 [11784719.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):833-41 [11821468.001]
  • [Cites] Urology. 2001 Oct;58(4):614-8 [11597555.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6276-80 [11507082.001]
  • [Cites] Med Hypotheses. 2001 Feb;56(2):213-6 [11425289.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):1942-52 [11344189.001]
  • [Cites] Endocrinology. 2001 Apr;142(4):1652-8 [11250947.001]
  • [Cites] Urology. 2001 Mar;57(3):471-5 [11248622.001]
  • [Cites] Eur J Endocrinol. 2001 Jan;144(1):29-36 [11174834.001]
  • [Cites] J Clin Invest. 2001 Jan;107(1):73-81 [11134182.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2000 Nov;46(7):1173-82 [11075947.001]
  • [Cites] Int J Urol. 2000 Sep;7(9):321-9 [11020056.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 6;92(23):1910-7 [11106682.001]
  • [Cites] Growth Horm IGF Res. 2000 Apr;10 Suppl A:S30-1 [10984283.001]
  • [Cites] J Natl Cancer Inst. 2000 Oct 4;92(19):1592-600 [11018095.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Jun;278(6):E967-76 [10826997.001]
  • [Cites] Growth Horm IGF Res. 1998 Jun;8(3):185-93 [10984306.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Jul 15;25(14):1765-70 [10888943.001]
  • [Cites] BJU Int. 2000 Jun;85(9):1134-42 [10848710.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):3058-64 [10850457.001]
  • [Cites] Endocrinology. 2000 Jun;141(6):2257-65 [10830316.001]
  • [Cites] Endocrinology. 2000 Jun;141(6):2254-6 [10830315.001]
  • [Cites] Endocrinology. 2000 Jun;141(6):2062-7 [10830291.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Mar;278(3):L545-51 [10710527.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Apr;85(4):1627-33 [10770208.001]
  • [Cites] Life Sci. 2000;66(2):91-103 [10666005.001]
  • [Cites] Prostate. 2000 Feb 15;42(3):203-10 [10639191.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):593-605 [16728585.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3024-33 [16540651.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Apr 14;342(3):851-8 [16499871.001]
  • [Cites] Int J Oncol. 2006 Mar;28(3):723-30 [16465378.001]
  • [Cites] Oncogene. 2005 Nov 10;24(49):7310-9 [16158061.001]
  • [Cites] Exp Mol Med. 2005 Oct 31;37(5):391-8 [16264263.001]
  • [Cites] Endocrinology. 2005 Oct;146(10):4445-55 [15994346.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):407-20 [15886048.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1270-3 [15894684.001]
  • [Cites] J Clin Pathol. 2005 Apr;58(4):361-6 [15790698.001]
  • [Cites] BJU Int. 2005 May;95(7):987-91 [15839919.001]
  • [Cites] Eur Urol. 2005 May;47(5):695-702 [15826765.001]
  • [Cites] Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 Mar;36(2):187-9 [15807262.001]
  • [Cites] Mol Cancer. 2005 Feb 2;4(1):7 [15686601.001]
  • [Cites] Breast Dis. 2003;17:49-59 [15687677.001]
  • [Cites] Oncol Rep. 2005 Feb;13(2):341-5 [15643522.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8620-9 [15574769.001]
  • [Cites] JAMA. 1965 Jun 28;192:1141-5 [14301034.001]
  • [Cites] Oncology. 1999 Nov;57(4):330-40 [10575321.001]
  • [Cites] J Natl Cancer Inst. 1999 Nov 17;91(22):1965-7 [10564682.001]
  • [Cites] Mol Cell Endocrinol. 1999 Sep 10;155(1-2):9-18 [10580834.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1758-64 [10528027.001]
  • [Cites] Endocrinology. 1998 Feb;139(2):807-10 [9449659.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4228-32 [10485462.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2B):1397-9 [10365112.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3098-103 [10077643.001]
  • [Cites] Endocrinology. 1999 May;140(5):2372-81 [10218991.001]
  • [Cites] J Endocrinol. 1998 Nov;159(2):227-32 [9795362.001]
  • [Cites] Endocrinology. 1998 Aug;139(8):3456-64 [9681496.001]
  • [Cites] Genomics. 1998 May 1;49(3):401-10 [9615225.001]
  • [Cites] J Biol Chem. 1998 Jul 3;273(27):16836-42 [9642243.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1713-20 [9589681.001]
  • [Cites] Endocrinology. 1998 May;139(5):2356-62 [9564845.001]
  • [Cites] J Urol. 1998 Apr;159(4):1379-83 [9507888.001]
  • [Cites] Endocrinology. 1997 Oct;138(10):4240-7 [9322936.001]
  • [Cites] J Biol Chem. 1997 Aug 15;272(33):20572-6 [9252371.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2308-13 [9215312.001]
  • [Cites] Endocrinology. 1997 Apr;138(4):1683-90 [9075731.001]
  • [Cites] Exp Cell Res. 1997 Feb 25;231(1):149-62 [9056422.001]
  • [Cites] J Cell Biochem. 1997 Jul 1;66(1):77-86 [9215530.001]
  • [Cites] Am J Physiol. 1996 Dec;271(6 Pt 1):L1014-22 [8997273.001]
  • [Cites] Endocrinol Metab Clin North Am. 1996 Sep;25(3):591-614 [8879988.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3774-82 [8855837.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4003-9 [15217931.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3988-95 [15217929.001]
  • [Cites] J Mol Endocrinol. 2004 Jun;32(3):859-68 [15171717.001]
  • [Cites] Gut. 2004 Jun;53(6):814-20 [15138207.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1600-3 [14996716.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):977-84 [14871828.001]
  • [Cites] Horm Metab Res. 2003 Nov-Dec;35(11-12):675-84 [14710346.001]
  • [Cites] Prostate. 2004 Jan 1;58(1):41-9 [14673951.001]
  • [Cites] Cancer Causes Control. 2003 Oct;14(8):721-6 [14674736.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13970-5 [14617774.001]
  • [Cites] Int J Cancer. 2004 Feb 20;108(5):773-9 [14696106.001]
  • [Cites] Endocrinology. 2003 Oct;144(10):4562-74 [12959972.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4315-21 [12907597.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3575-84 [12839944.001]
  • [Cites] Cancer Causes Control. 2003 Apr;14(3):285-92 [12814208.001]
  • [Cites] Endocrinology. 2003 Jul;144(7):2807-15 [12810534.001]
  • [Cites] Endocrinology. 2003 Jun;144(6):2417-24 [12746303.001]
  • [Cites] Endocrinology. 2003 Jun;144(6):2319-24 [12746292.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):14-9 [12672024.001]
  • [Cites] Growth Horm IGF Res. 2003 Feb;13(1):44-53 [12550081.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1566-73 [12496045.001]
  • [Cites] Practitioner. 1979 Feb;222(1328):211-7 [86186.001]
  • [Cites] Cancer Res. 1979 Jun;39(6 Pt 1):1973-9 [445396.001]
  • [Cites] CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40 [4625049.001]
  • [Cites] Proc Rudolf Virchow Med Soc City N Y. 1964;23:151-64 [5220432.001]
  • [Cites] Eur J Endocrinol. 2004 Aug;151 Suppl 1:S17-22 [15339239.001]
  • [Cites] Growth Horm IGF Res. 2004 Aug;14(4):277-86 [15231296.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2267-73 [17597108.001]
  • [Cites] Curr Cancer Drug Targets. 2007 Sep;7(6):591-604 [17896924.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1857-61 [17546599.001]
  • [Cites] BMC Cancer. 2007;7:136 [17651480.001]
  • [Cites] J Cell Physiol. 2007 Oct;213(1):261-8 [17492783.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1121-7 [17548673.001]
  • [Cites] Oncogene. 2007 Apr 5;26(16):2308-17 [17016438.001]
  • [Cites] Endocr Rev. 2007 Feb;28(1):20-47 [16931767.001]
  • [Cites] J Mol Biol. 2006 Dec 8;364(4):690-704 [17020769.001]
  • [Cites] World J Gastroenterol. 2006 Oct 21;12(39):6285-9 [17072950.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 May;66(5):405-17 [17483698.001]
  • [Cites] Growth Horm IGF Res. 2006 Aug;16(4):224-39 [16893667.001]
  • (PMID = 19956425.001).
  • [ISSN] 1943-8141
  • [Journal-full-title] American journal of translational research
  • [ISO-abbreviation] Am J Transl Res
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR016472
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2776314
  • [Keywords] NOTNLM ; Insulin-like growth factor, IGF / androgen insensitivity, AI / androgen sensitive, AS / neoplasm, bone, metastasis / prostate cancer, PCa
  •  go-up   go-down


19. Stelow EB, Debol SM, Stanley MW, Mallery S, Lai R, Bardales RH: Sampling of the adrenal glands by endoscopic ultrasound-guided fine-needle aspiration. Diagn Cytopathol; 2005 Jul;33(1):26-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sampling of the adrenal glands by endoscopic ultrasound-guided fine-needle aspiration.
  • Endoscopic ultrasound (EUS)-guided fine-needle aspiration (FNA) has proven to be a valuable modality for the primary diagnosis and staging of gastrointestinal, and perigastrointestinal malignancy.
  • Aside from assessing thoracic and abdominal lymph nodes and the liver for metastases, EUS can assess and sample the adrenal glands, which are frequently involved by metastatic disease, but can also harbor benign primary neoplasms.
  • The cytology files at our institution were reviewed for all cases of EUS-guided FNA of the adrenal glands.
  • Results were compared with overall EUS-guided FNA performance and the performance of non-EUS-guided FNA of the adrenal.
  • Between 1/1/00 and 5/15/04 there were 24 cases of EUS-guided FNA of the adrenal gland from 22 different patients (13 men; 9 women) at our institution.
  • This represented 1.4% of overall EUS-guided FNA and 77% of adrenal gland FNA.
  • Most patients had other cancers or mass lesions and were being staged at the time of the procedure (19 of 22).
  • Almost all FNAs were of the left adrenal gland (23 of 24).
  • Final diagnoses were as follows: cortical tissue consistent with cortical adenoma (19), metastatic adenocarcinoma (3), pheochromocytoma (1), and adrenal cortical carcinoma (1).
  • EUS-guided FNA of the adrenal gland is primarily used in the staging of other malignancies when lesions of the left adrenal are recognized sonographically.
  • Diagnostic tissue is easily obtained, including material for cell block IHC, which allows definitive diagnosis in cases that present difficult differential diagnoses.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Glands / pathology. Biopsy, Fine-Needle / methods. Endosonography / methods
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Adrenocortical Carcinoma / diagnosis. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Pheochromocytoma / diagnosis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2005 Wiley-Liss, Inc
  • (PMID = 15945088.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Novara G, Ficarra V, Antonelli A, Artibani W, Bertini R, Carini M, Cosciani Cunico S, Imbimbo C, Longo N, Martignoni G, Martorana G, Minervini A, Mirone V, Montorsi F, Schiavina R, Simeone C, Serni S, Simonato A, Siracusano S, Volpe A, Carmignani G, SATURN Project-LUNA Foundation: Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol; 2010 Oct;58(4):588-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed?
  • BACKGROUND: A new edition of the TNM was recently released that includes modifications for the staging system of kidney cancers.
  • Specifically, T2 cancers were subclassified into T2a and T2b (< or =10 cm vs >10 cm), tumors with renal vein involvement or perinephric fat involvement were classified as T3a cancers, and those with adrenal involvement were classified as T4 cancers.
  • OBJECTIVE: Our aim was to validate the recently released edition of the TNM staging system for primary tumor classification in kidney cancer.
  • MEASUREMENTS: Univariable and multivariable Cox regression models addressed cancer-specific survival (CSS) after surgery.
  • In multivariable analysis, the novel classification of the primary tumor was a powerful independent predictor of CSS (p for trend <0.0001).
  • CONCLUSIONS: The recently released seventh edition of the primary tumor staging system for kidney tumors is a powerful predictor of CSS.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Neoplasm Staging / standards

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • [CommentIn] J Urol. 2011 Apr;185(4):1223 [22115474.001]
  • [CommentIn] Eur Urol. 2010 Oct;58(4):517-9; discussion 519-21 [20728266.001]
  • [ErratumIn] Eur Urol. 2011 Jan;59(1):182. Schiavina, Roberto [corrected to Schiavina, Riccardo]
  • (PMID = 20674150.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Validation Studies
  • [Publication-country] Switzerland
  • [Investigator] De Cobelli O; Schiavina R; Antonelli A; Corti S; Cosciani Cunico S; Simeone C; Castelli M; Cimino S; Favilla V; Morgia G; Billia M; Terrone C; Volpe A; Imbimbo C; Longo N; Mirone V; Carini M; Masieri L; Minervini A; Serni S; Carmignani G; Oneto F; Simonato A; Varca V; Rocco F; Artibani W; Ficarra V; Novara G; Costantini E; Porena M; Zucchi A; Morgia G; Ciciliato S; Lampropoulou N; Siracusano S; Fontana D; Gontero P; Tizzani A; Brunelli M; Martignoni G; Valotto C; Zattoni F
  •  go-up   go-down


21. Bowes T, Singh B, Gupta RS: Subcellular localization of fumarase in mammalian cells and tissues. Histochem Cell Biol; 2007 Mar;127(3):335-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In thin sections from kidney, liver, heart, adrenal gland and anterior pituitary, strong and specific labeling due to fumarase antibody was only detected in mitochondria.
  • Although the cellular function of fumarase at these extramitochondrial locations is not known, the appearance/localization of fumarase outside mitochondria may help explain how mutations in this mitochondrial protein can give rise to a number of different types of cancers.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1980 Jun;77(6):3430-4 [6997878.001]
  • [Cites] Cell Biol Int. 2001;25(4):331-8 [11319839.001]
  • [Cites] J Biol Chem. 2000 Jul 7;275(27):20887-95 [10770938.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4130-5 [15024130.001]
  • [Cites] Rev Reprod. 1996 Jan;1(1):28-32 [9414435.001]
  • [Cites] Trends Biochem Sci. 2000 Nov;25(11):555-60 [11084368.001]
  • [Cites] EMBO J. 1998 Dec 1;17(23):6972-8 [9843503.001]
  • [Cites] Cell Stress Chaperones. 2006 Summer;11(2):116-28 [16817317.001]
  • [Cites] Mol Biol Cell. 1996 Jul;7(7):1003-14 [8862516.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 17;300(3):686-93 [12507504.001]
  • [Cites] J Assist Reprod Genet. 1997 Oct;14(9):492-5 [9401863.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 10;92 (21):9866-70 [7568234.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Aug 4;346(3):911-8 [16774737.001]
  • [Cites] Cell Stress Chaperones. 2002 Oct;7(4):317-29 [12653476.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):32056-63 [11350955.001]
  • [Cites] J Biol Chem. 2004 Jul 23;279(30):31544-55 [15155745.001]
  • [Cites] J Cell Sci. 1994 Mar;107 ( Pt 3):539-49 [7911805.001]
  • [Cites] Biochem J. 1990 Nov 15;272(1):119-26 [2264815.001]
  • [Cites] Eur J Biochem. 1994 Jun 1;222(2):551-60 [7912672.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10425-30 [9724719.001]
  • [Cites] J Biol Chem. 2000 Feb 4;275(5):3305-12 [10652318.001]
  • [Cites] J Biochem. 1984 Jul;96(1):189-95 [6333419.001]
  • [Cites] J Histochem Cytochem. 2000 Jan;48(1):45-56 [10653585.001]
  • [Cites] Exp Cell Res. 2000 Oct 10;260(1):30-9 [11010808.001]
  • [Cites] Biochem J. 2000 Feb 1;345 Pt 3:423-7 [10642497.001]
  • [Cites] Immunol Rev. 2001 Apr;180:65-77 [11414365.001]
  • [Cites] Histochem Cell Biol. 2005 Nov;124(5):409-21 [16133117.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45109-16 [12960177.001]
  • [Cites] DNA Cell Biol. 1992 Jul-Aug;11(6):489-96 [1524681.001]
  • [Cites] Expert Rev Mol Med. 2000 Sep 15;2(8):1-17 [14585136.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6237-42 [15069201.001]
  • [Cites] Mol Genet Metab. 1998 Apr;63(4):254-62 [9635293.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Aug 18;275(1):174-9 [10944461.001]
  • [Cites] Histochem Cell Biol. 2000 Sep;114(3):245-55 [11083468.001]
  • [Cites] Mol Cell Biol. 1999 May;19(5):3869-76 [10207110.001]
  • [Cites] J Biol Chem. 1993 Nov 5;268(31):23157-61 [7901206.001]
  • [Cites] Int Rev Cytol. 2000;194:133-96 [10494626.001]
  • [Cites] Mitochondrion. 2004 May;3(6):315-25 [16120363.001]
  • [Cites] Exp Cell Res. 2003 May 15;286(1):96-101 [12729798.001]
  • [Cites] Exp Cell Res. 1996 Jan 10;222(1):16-27 [8549659.001]
  • [Cites] J Biol Chem. 1998 Oct 2;273(40):25587-93 [9748223.001]
  • [Cites] J Biol Chem. 1989 Feb 15;264(5):2581-6 [2914923.001]
  • [Cites] Circ Res. 1994 Dec;75(6):1078-85 [7525102.001]
  • [Cites] Biochem Soc Trans. 2006 Jun;34(Pt 3):370-3 [16709164.001]
  • [Cites] Trends Biochem Sci. 1999 May;24(5):174-7 [10322429.001]
  • [Cites] J Pathol. 2003 Feb;199(2):237-42 [12533837.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):46111-7 [11585823.001]
  • [Cites] Histol Histopathol. 2002 Apr;17 (2):353-64 [11962739.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar;281(5):1161-9 [11243856.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):193-202 [12612654.001]
  • [Cites] Eur J Cell Biol. 2003 May;82(5):240-52 [12800979.001]
  • [Cites] Am J Physiol. 1993 Nov;265(5 Pt 1):G894-902 [8238519.001]
  • [Cites] Mol Cell Proteomics. 2006 Feb;5(2):306-12 [16278343.001]
  • [Cites] J Histochem Cytochem. 2003 Feb;51(2):215-26 [12533530.001]
  • [Cites] J Histochem Cytochem. 1996 Jul;44(7):743-9 [8675995.001]
  • [Cites] Mol Gen Genet. 1991 Oct;229(3):413-20 [1944230.001]
  • [Cites] J Cell Biol. 1967 Aug;34(2):597-615 [6035648.001]
  • [Cites] Exp Cell Res. 1997 Aug 1;234(2):205-16 [9260887.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):858-62 [7905632.001]
  • [Cites] Eur J Biochem. 1992 Jul 15;207(2):767-72 [1633825.001]
  • [Cites] Trends Cell Biol. 1992 Dec;2(12):369-75 [14731958.001]
  • [Cites] Cell. 1990 Mar 23;60(6):971-80 [2317868.001]
  • [Cites] Mol Cell Biol. 1994 Jul;14(7):4770-8 [8007976.001]
  • [Cites] Mol Biol Cell. 2002 May;13(5):1439-48 [12006643.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):17-22 [14695314.001]
  • [Cites] Histochem Cell Biol. 2001 Dec;116(6):507-17 [11810192.001]
  • (PMID = 17111171.001).
  • [ISSN] 0948-6143
  • [Journal-full-title] Histochemistry and cell biology
  • [ISO-abbreviation] Histochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Indicators and Reagents; EC 4.2.1.2 / Fumarate Hydratase; KOO5CM684H / Digitonin
  •  go-up   go-down


22. Freddi S, Arnaldi G, Fazioli F, Scarpelli M, Appolloni G, Mancini T, Kola B, Bertagna X, Mantero F, Collu R, Boscaro M: Expression of growth hormone-releasing hormone receptor splicing variants in human primary adrenocortical tumours. Clin Endocrinol (Oxf); 2005 May;62(5):533-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Several splice variants (SVs) of GHRH receptor (GHRH-R) have been identified in various human cancers through which GHRH antagonists may exert their IGF-II-mediated antiproliferative action.
  • Because the overexpression of the IGF-II gene is a frequent feature of adrenal carcinoma, we searched for the presence of GHRH-R SVs in these tumours.
  • SV2 was detected in five of 24 cancers examined, whereas the incidence of SV1 and SV4 was lower.
  • No PCR products for SV3 or wild-type GHRH-R were found in carcinomas; mRNA for wild-type GHRH-R or SVs of GHRH-R were not observed either in adenomas or in normal adrenal or in NCI-H295R cells.
  • CONCLUSION: This is the first time that the expression of splice variants of GHRH-R has been demonstrated in human adrenal carcinoma.
  • This study raises the possibility that splice variants might play a role in adrenal carcinogenesis and might offer the possibility for new therapeutic strategies at least in a subgroup of adrenal carcinomas.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Alternative Splicing. Carcinoma / genetics. Polymorphism, Genetic. RNA, Messenger / analysis. Receptors, Neuropeptide / genetics. Receptors, Pituitary Hormone-Regulating Hormone / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adolescent. Adult. Aged. Base Sequence. Cell Line, Tumor. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15853821.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Neuropeptide; 0 / Receptors, Pituitary Hormone-Regulating Hormone; 0 / somatotropin releasing hormone receptor
  •  go-up   go-down


23. Nadeau ME, Kaartinen MJ, Laguë MN, Paquet M, Huneault LM, Boerboom D: A mouse surgical model for metastatic ovarian granulosa cell tumor. Comp Med; 2009 Dec;59(6):553-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mouse surgical model for metastatic ovarian granulosa cell tumor.
  • However, because the primary tumors killed their hosts before metastases were able to form, the use of these mice to study metastatic disease required the development of a simple, reliable, and humane surgical protocol for the excision of large GCTs from debilitated mice.
  • Here we describe a protocol involving multimodal anesthesia, tumor removal through ventral midline celiotomy and perioperative fluid therapy, and analgesia that led to the postoperative survival of more than 90% of mice, despite the removal of tumors representing as much as 10% of the animal's body weight.
  • Intraabdominal recurrence of the GCT did not occur in surviving animals, but most developed pulmonary or adrenal metastases (or both) by 12 wk after surgery.
  • Furthermore, our results delineate anesthetic and surgical principles for the removal of large abdominal tumors from mice that will be applicable to other models of human cancers.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Vet Clin North Am Exot Anim Pract. 2001 Jan;4(1):169-91 [11217459.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1180-9 [12637488.001]
  • [Cites] Reprod Biol Endocrinol. 2003 Oct 7;1:67 [14613552.001]
  • [Cites] Carcinogenesis. 2009 May;30(5):869-78 [19237610.001]
  • [Cites] Int J Gynecol Pathol. 2007 Apr;26(2):154-9 [17413982.001]
  • [Cites] Carcinogenesis. 2008 Nov;29(11):2062-72 [18687666.001]
  • [Cites] J Obstet Gynaecol Can. 2005 Apr;27(4):363-4 [15937611.001]
  • (PMID = 20034430.001).
  • [ISSN] 1532-0820
  • [Journal-full-title] Comparative medicine
  • [ISO-abbreviation] Comp. Med.
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2798836
  •  go-up   go-down


24. Lachenmayer A, Lichtenauer UD, Cox T, Schott M, Malendowicz LK, Goretzki PE, Cupisti K, Scherbaum WA, Bornstein SR, Willenberg HS: Nestin as a marker in the classification of adrenocortical tumors. Horm Metab Res; 2009 May;41(5):397-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since adrenocortical carcinoma, a tumor entity still very difficult to classify, may gain the ability to aberrantly express neuroectodermal proteins including chromogranin A and synaptophysin, we asked the question whether nestin might also be detected in adrenocortical carcinomas, and if so, whether it might serve as a tool for clinical pathology.
  • Therefore, we studied the expression of nestin in normal adrenal glands, adrenocortical adenomas, and adrenocortical cancers using specific immunohistochemistry and semi-quantitative reverse transcriptase-polymerase chain reaction.
  • Immunostaining was nestin-positive in 1 out of 9 normal adrenal glands (11%), 2 out of 20 adrenocortical adenomas (10%), and 13 out of 16 adrenocortical carcinomas (81%).
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Adenoma / classification. Adrenocortical Carcinoma / pathology. Biomarkers, Tumor / metabolism. Intermediate Filament Proteins / metabolism. Nerve Tissue Proteins / metabolism
  • [MeSH-minor] Adrenal Glands / metabolism. Adult. Aged. Aged, 80 and over. Female. Gene Expression. Humans. Male. Middle Aged. Nestin

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19294612.001).
  • [ISSN] 1439-4286
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  •  go-up   go-down


25. Advani A, Johnson SJ, Nicol MR, Papacleovoulou G, Evans DB, Vaikkakara S, Mason JI, Quinton R: Adult-onset hypogonadotropic hypogonadism caused by aberrant expression of aromatase in an adrenocortical adenocarcinoma. Endocr J; 2010;57(7):651-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Estrogen-secreting adrenal cancers are extremely rare, with feminizing symptoms attributed to aromatase expression in the adrenal tumor.
  • A right adrenal mass was identified on CT scanning and the patient underwent an open adrenalectomy.
  • Immunohistochemistry of the adrenal cancer confirmed aberrant expression of aromatase in most, although not all, carcinoma cells.
  • Transcripts associated with utilization of promoters II, I.1 and I.3 were prominently represented in the tumor aromatase mRNA.
  • This case highlights that clinical features of feminizing adrenocortical carcinomas can be secondary to estrogen production by aberrantly transcribed and translated aromatase within the tumor.
  • The diagnosis of adrenocortical adenocarcinoma should be considered in men presenting with low testosterone and gonadotropins, particularly in the presence of feminizing features.
  • [MeSH-major] Adenocarcinoma / genetics. Adrenal Cortex Neoplasms / genetics. Aromatase / genetics. Hypogonadism / genetics

  • Genetic Alliance. consumer health - Hypogonadism, isolated, hypogonadotropic.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20467160.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 1.14.14.1 / Aromatase
  •  go-up   go-down


26. Ohta S, Lai EW, Morris JC, Bakan DA, Klaunberg B, Cleary S, Powers JF, Tischler AS, Abu-Asab M, Schimel D, Pacak K: MicroCT for high-resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice. Int J Cancer; 2006 Nov 1;119(9):2236-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Successful outcomes for patients with cancer often depend on the early detection of tumor and the prompt initiation of active therapy.
  • Despite major advances in the treatment of many cancers, early-stage lesions often go undetected due to the suboptimal resolution of current anatomical and functional imaging modalities.
  • This limitation also applies to preclinical animal tumor models that are crucial for the evaluation and development of new therapeutic approaches to cancer.
  • Furthermore, we show that in vivo microCT imaging enhanced using a hepatobiliary-specific contrast agent, glyceryl-2-oleyl-1,3-di-7-(3-amino-2,4,6-triiodophenyl)-heptanoate (DHOG), detected tumors as small as 0.35 mm as early as 4 weeks after the injection of the tumor cells.
  • This model may be useful for in vivo studies of tumor biology and for development of new strategies to treat metastatic pheochromocytoma.

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • COS Scholar Universe. author profiles.
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Relat Cancer. 2004 Sep;11(3):423-36 [15369446.001]
  • [Cites] J Neurosci. 1993 Mar;13(3):1280-91 [7680068.001]
  • [Cites] J Med Chem. 1995 Feb 17;38(4):636-46 [7861412.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):765-89 [9735133.001]
  • [Cites] Urology. 1999 Apr;53(4):679-83 [10197840.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):755-64; discussion 764-6 [10363888.001]
  • [Cites] Mol Imaging. 2004 Jul;3(3):149-58 [15530250.001]
  • [Cites] Cell Tissue Res. 2005 Dec;322(3):443-53 [16047163.001]
  • [Cites] Mol Psychiatry. 2002;7(9):967-74 [12399950.001]
  • [Cites] Radiat Res. 2003 Mar;159(3):320-7 [12600234.001]
  • [Cites] Acad Radiol. 2002 May;9 Suppl 1:S200-4 [12019869.001]
  • [Cites] Invest Radiol. 2000 Mar;35(3):158-69 [10719825.001]
  • [Cites] Radiology. 2000 Sep;216(3):865-71 [10966724.001]
  • [Cites] Cell Tissue Res. 2000 Dec;302(3):309-20 [11151443.001]
  • [Cites] Ann Intern Med. 2001 Feb 20;134(4):315-29 [11182843.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2968-73 [11306475.001]
  • [Cites] Skeletal Radiol. 2001 Feb;30(2):94-8 [11310206.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):1999-2008 [11344198.001]
  • [Cites] Am J Ther. 2001 Sep-Oct;8(5):359-65 [11550077.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):883-95 [15168351.001]
  • [Cites] Surgery. 2004 Aug;136(2):183-9 [15300178.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5632-42 [15313901.001]
  • [Cites] J Surg Res. 2004 Jun 1;119(1):41-5 [15126080.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):81-91 [12746566.001]
  • [Cites] Endocr Rev. 2003 Aug;24(4):539-53 [12920154.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6265-71 [14559813.001]
  • [Cites] Science. 2003 Dec 12;302(5652):1880-2 [14671264.001]
  • (PMID = 16841334.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS037685; United States / Intramural NIH HHS / / Z99 CA999999; United States / NINDS NIH HHS / NS / R01 NS 37685
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ NIHMS43416; NLM/ PMC2288741
  •  go-up   go-down


27. Wolkersdörfer GW, Marx C, Brown J, Schröder S, Füssel M, Rieber EP, Kuhlisch E, Ehninger G, Bornstein SR: Prevalence of HLA-DRB1 genotype and altered Fas/Fas ligand expression in adrenocortical carcinoma. J Clin Endocrinol Metab; 2005 Mar;90(3):1768-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A distinctive feature of malignant adrenocortical neoplasms is decreased major histocompatibility complex (MHC) class II molecule expression.
  • Therefore, MHC class II phenotype and genotype and expression patterns of the Fas/Fas ligand system were investigated in 24 adrenocortical tumors (n(Adenomas) = 14, n(Carcinomas) = 10) and an adrenal cancer cell line (NCI-H295).
  • In summary, the DRB1*01 genotype may be correlated to a higher risk for malignancy.
  • Additional studies on MHC class II genotype and phenotype and the altered Fas/Fas ligand system in adrenal neoplasms may help to identify mechanisms of immune escape and suggest new diagnostic approaches.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenocortical Carcinoma / genetics. Antigens, CD95 / metabolism. HLA-DR Antigens / genetics. Membrane Glycoproteins / metabolism

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15585555.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / HLA-DR Antigens; 0 / HLA-DRB1 Chains; 0 / Membrane Glycoproteins
  •  go-up   go-down


28. Katanoda K, Hayashi K, Yamamoto K, Sobue T: Secular trends in neuroblastoma mortality before and after the cessation of national mass screening in Japan. J Epidemiol; 2009;19(5):266-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Utilizing vital statistics data from 1980 through 2006, we analyzed the secular trends in NB mortality by using cancer of the adrenal gland as a surrogate.
  • RESULTS: The number of deaths from cancer of the adrenal gland was closely correlated with the number of deaths from NB.


29. Berthon A, Sahut-Barnola I, Lambert-Langlais S, de Joussineau C, Damon-Soubeyrand C, Louiset E, Taketo MM, Tissier F, Bertherat J, Lefrançois-Martinez AM, Martinez A, Val P: Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Genet; 2010 Apr 15;19(8):1561-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development.
  • Adrenocortical carcinoma is a rare but aggressive cancer with unknown aetiology.
  • Constitutive activation of beta-catenin is the most frequent alteration in benign and malignant adrenocortical tumours in patients.
  • Here, we show that constitutive activation of beta-catenin in the adrenal cortex of transgenic mice resulted in progressive steroidogenic and undifferentiated spindle-shaped cells hyperplasia as well as dysplasia of the cortex and medulla.
  • Over a 17 months time course, transgenic adrenals developed malignant characteristics such as uncontrolled neovascularization and loco-regional metastatic invasion.
  • Altogether these observations demonstrate that constitutively active beta-catenin is an adrenal oncogene which triggers benign aldosterone-secreting tumour development and promotes malignancy.
  • [MeSH-major] Adrenal Cortex / pathology. Adrenal Gland Neoplasms / metabolism. Adrenal Gland Neoplasms / pathology. beta Catenin / metabolism
  • [MeSH-minor] Aldosterone / metabolism. Animals. Cell Proliferation. Disease Models, Animal. Humans. Hyperplasia. Mice. Mice, Inbred C57BL. Mice, Transgenic. Neoplasm Metastasis


30. Yoon M, Kim S: Retroperitoneal Pleomorphic Liposarcoma Mimicking Adrenal Cancer in F-18 FDG PET/CT. Nucl Med Mol Imaging; 2010 Sep;44(3):230-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal Pleomorphic Liposarcoma Mimicking Adrenal Cancer in F-18 FDG PET/CT.
  • We present the case of a 42-year-old man who had experienced intermittent left flank pain for a month.
  • Positron emission tomography/computed tomography (PET/CT) with F-18 fluoro-2-deoxy-D-glucose (F-18 FDG) showed intense uptake in the retroperitoneal mass, which mimicked an adrenal cancer.
  • The patient underwent left radical nephroadrenalectomy, and the tumor was revealed to be a pleomorphic liposarcoma upon pathological examination.
  • When there is a large retroperitoneal mass with intense F-18 FDG activity, the possibility of a pleomorphic liposarcoma should be considered.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24899957.001).
  • [ISSN] 1869-3474
  • [Journal-full-title] Nuclear medicine and molecular imaging
  • [ISO-abbreviation] Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC4042936
  • [Keywords] NOTNLM ; Adrenal cancer / F-18 FDG / Liposarcoma / PET/CT / Pleomorphic / Retroperitoneal
  •  go-up   go-down


31. Bergheim I, McClain CJ, Arteel GE: Treatment of alcoholic liver disease. Dig Dis; 2005;23(3-4):275-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For example, the Veterans Administration Cooperative Studies reported that patients with cirrhosis and superimposed alcoholic hepatitis had a 4-year mortality of >60% (worse than many common cancers such as breast and prostate).

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • [Cites] Hepatology. 1996 Feb;23(2):240-8 [8591847.001]
  • [Cites] Gastroenterology. 1996 Jun;110(6):1847-53 [8964410.001]
  • [Cites] Hepatology. 1996 Oct;24(4):820-3 [8855183.001]
  • [Cites] N Engl J Med. 1997 Aug 14;337(7):473-9 [9250851.001]
  • [Cites] FASEB J. 1997 Oct;11(12):1013-9 [9337154.001]
  • [Cites] Hepatology. 2000 Apr;31(4):864-71 [10733541.001]
  • [Cites] Nutrition. 2000 Apr;16(4):296-302 [10758367.001]
  • [Cites] Hepatology. 2000 Jul;32(1):36-42 [10869286.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Aug;12(8):941-8 [10958223.001]
  • [Cites] Gastroenterology. 2000 Dec;119(6):1637-48 [11113085.001]
  • [Cites] J Hepatol. 2000 Dec;33(6):907-14 [11131452.001]
  • [Cites] Gastroenterology. 2001 Feb;120(3):726-48 [11179247.001]
  • [Cites] Hepatology. 2001 Feb;33(2):464-70 [11172350.001]
  • [Cites] Transplantation. 2001 Aug 27;72(4):619-26 [11544420.001]
  • [Cites] J Hepatol. 2002 Jan;36(1):130-7 [11804676.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Apr;14(4):377-81 [11943949.001]
  • [Cites] Hepatology. 1997 Dec;26(6):1530-7 [9397994.001]
  • [Cites] J Hepatol. 1998 Apr;28(4):615-21 [9566830.001]
  • [Cites] JPEN J Parenter Enteral Nutr. 1999 Jan-Feb;23(1):1-6 [9888410.001]
  • [Cites] J Hepatol. 1999 Jun;30(6):1081-9 [10406187.001]
  • [Cites] J Hepatol. 1999 Jun;30(6):1130-7 [10406193.001]
  • [Cites] J Am Coll Nutr. 1999 Oct;18(5):434-41 [10511325.001]
  • [Cites] Ann Intern Med. 2005 Jan 4;142(1):37-46 [15537682.001]
  • [Cites] J Clin Gastroenterol. 2005 Mar;39(3):232-6 [15718866.001]
  • [Cites] J Am Med Assoc. 1948 Oct 23;138(8):543-9 [18886770.001]
  • [Cites] Gastroenterology. 2003 May;124(5):1488-99 [12730887.001]
  • [Cites] Dig Dis Sci. 1985 Apr;30(4):329-33 [3979239.001]
  • [Cites] Digestion. 1985;32(4):238-42 [4065445.001]
  • [Cites] Gastroenterology. 1987 Jan;92(1):208-14 [3781189.001]
  • [Cites] Hepatology. 1987 Jan-Feb;7(1):122-8 [3804191.001]
  • [Cites] Alcohol Clin Exp Res. 1986 Dec;10(6):582-9 [3544908.001]
  • [Cites] N Engl J Med. 1988 Jun 30;318(26):1709-13 [3287167.001]
  • [Cites] Clin Biochem. 1999 Oct;32(7):563-70 [10614719.001]
  • [Cites] J Hepatol. 2002 Apr;36(4):480-7 [11943418.001]
  • [Cites] Am J Gastroenterol. 2002 Jul;97(7):1674-81 [12135017.001]
  • [Cites] Alcohol. 2002 Jul;27(3):185-92 [12163148.001]
  • [Cites] J Nutr. 2002 Aug;132(8 Suppl):2367S-2372S [12163694.001]
  • [Cites] Neurology. 2002 Aug 27;59(4):601-5 [12196657.001]
  • [Cites] Eur J Clin Pharmacol. 2002 Sep;58(6):435-40 [12242604.001]
  • [Cites] Hepatology. 2002 Nov;36(5):1206-13 [12395331.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Dec 6;299(3):459-64 [12445823.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(1):CD003045 [12535450.001]
  • [Cites] J Hepatol. 2003 Apr;38(4):419-25 [12663232.001]
  • [Cites] J Hepatol. 2003 May;38(5):629-34 [12713874.001]
  • [Cites] Gastroenterology. 2003 May;124(6):1700-10 [12761727.001]
  • [Cites] Alcohol Clin Exp Res. 2003 Nov;27(11):1757-64 [14634491.001]
  • [Cites] J Hepatol. 2004 Jan;40(1):40-6 [14672612.001]
  • [Cites] Alcohol Clin Exp Res. 2004 Jan;28(1):173-81 [14745316.001]
  • [Cites] Am J Gastroenterol. 2004 Feb;99(2):255-60 [15046213.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):1959-66 [15161632.001]
  • [Cites] Liver Transpl. 2004 Jul;10(7):886-97 [15237373.001]
  • [Cites] Pharmacology. 2004 Aug;71(4):199-208 [15240996.001]
  • [Cites] Hepatology. 2004 Oct;40(4):989-97 [15382170.001]
  • [Cites] Lancet. 2004 Oct 2-8;364(9441):1219-28 [15464182.001]
  • [Cites] Am J Med. 1968 Mar;44(3):406-20 [5641303.001]
  • [Cites] Ann Intern Med. 1971 Mar;74(3):311-21 [4928161.001]
  • [Cites] Gastroenterology. 1978 Aug;75(2):193-9 [352788.001]
  • [Cites] Acta Med Scand. 1979;205(5):361-6 [375690.001]
  • [Cites] Gastroenterology. 1980 Mar;78(3):524-9 [6985881.001]
  • [Cites] Clin Gastroenterol. 1981 May;10(2):417-41 [7018751.001]
  • [Cites] Am J Med. 1984 Feb;76(2):211-22 [6421159.001]
  • [Cites] J Biol Chem. 1988 Nov 25;263(33):17205-8 [3053703.001]
  • [Cites] Hepatology. 1988 Nov-Dec;8(6):1605-9 [3192174.001]
  • [Cites] Dan Med Bull. 1988 Dec;35(6):564-75 [3064977.001]
  • [Cites] Ann Intern Med. 1989 May 1;110(9):685-90 [2648927.001]
  • [Cites] J Hepatol. 1989 Jul;9(1):105-13 [2671116.001]
  • [Cites] Hepatology. 1991 May;13(5):896-901 [1851493.001]
  • [Cites] Hepatology. 1991 Dec;14(6):1029-34 [1959850.001]
  • [Cites] Gastroenterology. 1992 Jan;102(1):200-5 [1727754.001]
  • [Cites] N Engl J Med. 1992 Feb 20;326(8):507-12 [1531090.001]
  • [Cites] Am J Gastroenterol. 1993 Jan;88(1):39-43 [7678368.001]
  • [Cites] JPEN J Parenter Enteral Nutr. 1993 Mar-Apr;17(2):119-24 [8455312.001]
  • [Cites] Gastroenterology. 1993 Apr;104(4):1133-8 [8462803.001]
  • [Cites] Gastroenterology. 1993 Jul;105(1):229-36 [8514039.001]
  • [Cites] Hepatology. 1993 Jun;17(6):1066-73 [8514256.001]
  • [Cites] Alcohol Clin Exp Res. 1993 Jun;17(3):687-9 [8392819.001]
  • [Cites] Lancet. 1994 Aug 20;344(8921):502-7 [7914613.001]
  • [Cites] J Am Coll Nutr. 1995 Apr;14(2):192-6 [7790695.001]
  • [Cites] Alcohol Clin Exp Res. 1995 Jun;19(3):635-41 [7573786.001]
  • [Cites] J Clin Invest. 1995 Nov;96(5):2461-8 [7593635.001]
  • (PMID = 16508292.001).
  • [ISSN] 0257-2753
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / AA003624-26; United States / NIAAA NIH HHS / AA / R01 AA003624-26; United States / NIAAA NIH HHS / AA / AA003624-27A1; United States / NIAAA NIH HHS / AA / R01 AA003624-27A1; United States / NIAAA NIH HHS / AA / R01 AA003624
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Enzyme Inhibitors; SD6QCT3TSU / Pentoxifylline
  • [Number-of-references] 82
  • [Other-IDs] NLM/ NIHMS88322; NLM/ PMC2636549
  •  go-up   go-down


32. Hamid T, Malik MT, Millar RP, Kakar SS: Protein kinase A serves as a primary pathway in activation of Nur77 expression by gonadotropin-releasing hormone in the LbetaT2 mouse pituitary gonadotroph tumor cell line. Int J Oncol; 2008 Nov;33(5):1055-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein kinase A serves as a primary pathway in activation of Nur77 expression by gonadotropin-releasing hormone in the LbetaT2 mouse pituitary gonadotroph tumor cell line.
  • It plays an important role in a number of biological processes, including regulation of signaling functions in the hypothalamo-pituitary-adrenal axis, regulation of thymocyte apoptosis, regulation of steroidogenesis and regulation of tumor cell proliferation and apoptosis.
  • In addition to pituitary, the presence of GnRH high affinity receptors has been reported in various cancers and cancer cell lines.
  • In addition, GnRH and its analogs are clinically used in the treatment of prostate cancer.
  • [MeSH-major] Cyclic AMP-Dependent Protein Kinases / metabolism. DNA-Binding Proteins / metabolism. Gonadotrophs / enzymology. Gonadotropin-Releasing Hormone / metabolism. Pituitary Neoplasms / enzymology. Receptors, Steroid / metabolism. Signal Transduction
  • [MeSH-minor] Animals. Calcium / metabolism. Cell Line, Tumor. Chelating Agents / pharmacology. Cyclic AMP / metabolism. Dose-Response Relationship, Drug. Enzyme Activators / pharmacology. Mice. Mitogen-Activated Protein Kinases / antagonists & inhibitors. Mitogen-Activated Protein Kinases / metabolism. Nuclear Receptor Subfamily 4, Group A, Member 1. Protein Kinase Inhibitors / pharmacology. RNA, Messenger / metabolism. Time Factors. Up-Regulation

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949369.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127681325; United States / NCI NIH HHS / CA / CA60871
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Chelating Agents; 0 / DNA-Binding Proteins; 0 / Enzyme Activators; 0 / Nr4a1 protein, mouse; 0 / Nuclear Receptor Subfamily 4, Group A, Member 1; 0 / Protein Kinase Inhibitors; 0 / RNA, Messenger; 0 / Receptors, Steroid; 33515-09-2 / Gonadotropin-Releasing Hormone; 79561-22-1 / LHRH, Ala(6)-Gly(10)-ethylamide-; E0399OZS9N / Cyclic AMP; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; SY7Q814VUP / Calcium
  •  go-up   go-down


33. Gola M, Doga M, Bonadonna S, Mazziotti G, Vescovi PP, Giustina A: Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects. Pituitary; 2006;9(3):221-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Excessive peripheral production of GHRH by a tumor source would therefore be expected to cause somatotroph cell hyperstimulation, increased GH secretion and eventually pituitary acromegaly.
  • Immunoreactive GHRH is present in several tumors, including carcinoid tumors, pancreatic cell tumors, small cell lung cancers, endometrial tumors, adrenal adenomas, and pheochromocytomas which have been reported to secrete GHRH.
  • Unique and unexpected clinical features in an acromegalic patient, including respiratory wheezing or dyspnea, facial flushing, peptic ulcers, or renal stones sometimes are helpful in alerting the physician to diagnosing non pituitary endocrine tumors.
  • Surgical resection of the tumor secreting ectopic GHRH should be the logical approach to a patient with ectopic GHRH syndrome.
  • In fact, long-acting somatostatin analogs may be able to control not only the ectopic hormonal secretion syndrome, but also, in some instances, tumor growth.
  • [MeSH-major] Acromegaly / etiology. Adenoma / secretion. Carcinoid Tumor / secretion. Growth Hormone-Releasing Hormone / secretion. Growth Hormone-Secreting Pituitary Adenoma / secretion. Neuroendocrine Tumors / secretion. Paraneoplastic Endocrine Syndromes / etiology
  • [MeSH-minor] Animals. Biomarkers, Tumor / blood. Diagnosis, Differential. Human Growth Hormone / blood. Humans. Insulin-Like Growth Factor I / metabolism. Treatment Outcome. Up-Regulation

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):539-51 [1521511.001]
  • [Cites] Endocrinology. 1997 Nov;138(11):4543-51 [9348176.001]
  • [Cites] Eur J Endocrinol. 2005 Dec;153(6):737-40 [16322377.001]
  • [Cites] Semin Oncol. 1987 Sep;14(3):343-53 [2820064.001]
  • [Cites] Biochem Biophys Res Commun. 1982 Nov 16;109(1):152-8 [7159418.001]
  • [Cites] Endocrinology. 1985 Aug;117(2):457-67 [2862007.001]
  • [Cites] Endocr J. 1993 Feb;40(1):133-9 [7951487.001]
  • [Cites] J Endocrinol Invest. 1993 Sep;16(8):585-90 [8258646.001]
  • [Cites] Nature. 1983 Feb 17-23;301(5901):607-8 [6402707.001]
  • [Cites] Endocr Rev. 1998 Dec;19(6):717-97 [9861545.001]
  • [Cites] Endocr Rev. 1988 Aug;9(3):357-73 [3145190.001]
  • [Cites] Metabolism. 1991 May;40(5):519-23 [2023538.001]
  • [Cites] Domest Anim Endocrinol. 1997 Sep;14(5):358-66 [9347256.001]
  • [Cites] J Neurosci. 1996 Dec 15;16(24):8140-8 [8987839.001]
  • [Cites] J Endocrinol Invest. 2003 Feb;26(2):163-9 [12739745.001]
  • [Cites] Nature. 1983 Jun 9-15;303(5917):532-5 [6406907.001]
  • [Cites] J Clin Endocrinol Metab. 1984 May;58(5):796-803 [6423659.001]
  • [Cites] J Clin Endocrinol Metab. 1989 May;68(5):917-24 [2565913.001]
  • [Cites] Proc Soc Exp Biol Med. 1990 Mar;193(3):232-5 [2106141.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1356-9; discussion 1360 [12015856.001]
  • [Cites] J Neuroendocrinol. 1989 Apr 1;1(2):109-15 [19210467.001]
  • [Cites] Endocrinology. 1976 Mar;98(3):580-9 [177264.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Mar;54(3):301-7 [11298081.001]
  • [Cites] Neuroendocrinology. 1990 May;51(5):572-5 [1693757.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Nov;80(11):3321-6 [7593445.001]
  • [Cites] Metabolism. 1990 Sep;39(9 Suppl 2):40-2 [1976218.001]
  • [Cites] N Engl J Med. 1990 Aug 2;323(5):322-7 [2164153.001]
  • [Cites] Endocrinology. 1984 Nov;115(5):2032-4 [6436012.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2797-802 [12788890.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Aug;59(2):197-201 [6330151.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2104-9 [15671091.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Apr;82(4):1210-9 [9100598.001]
  • [Cites] Endocrinology. 1993 Sep;133(3):1029-34 [8103446.001]
  • [Cites] Pharmacol Res. 1996 Nov-Dec;34(5-6):247-68 [9076850.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Nov;59(5):846-9 [6434585.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):221-6 [2891432.001]
  • [Cites] Metabolism. 1992 Dec;41(12):1291-4 [1281259.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S89-94 [11762359.001]
  • [Cites] Endocrinol Jpn. 1989 Apr;36(2):229-36 [2550207.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jan;68(1):180-5 [2491860.001]
  • [Cites] J Clin Invest. 1980 Jan;65(1):43-54 [6243140.001]
  • [Cites] Physiol Rev. 1999 Apr;79(2):511-607 [10221989.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Jan;68(1):22-8 [2491864.001]
  • [Cites] Clin Endocrinol (Oxf). 1987 Sep;27(3):297-306 [2892599.001]
  • [Cites] FEBS Lett. 1996 Sep 23;394(1):1-4 [8925914.001]
  • [Cites] J Clin Endocrinol Metab. 1987 Mar;64(3):585-91 [3102543.001]
  • [Cites] Endocrinology. 1985 Jul;117(1):424-6 [2988927.001]
  • [Cites] J Endocrinol Invest. 2003;26(8 Suppl):4-7 [15233203.001]
  • [Cites] Nature. 1982 Nov 18;300(5889):276-8 [6292724.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):17-24 [1973173.001]
  • [Cites] Endocrinology. 1972 Oct;91(4):1071-8 [5051331.001]
  • [Cites] J Endocrinol Invest. 2003 Dec;26(12):1242-7 [15055479.001]
  • [Cites] J Endocrinol Invest. 2005;28(11 Suppl International):43-7 [16625844.001]
  • [Cites] J Clin Invest. 1982 Nov;70(5):965-77 [6290540.001]
  • [Cites] Endocr Rev. 1991 Nov;12(4):450-82 [1684746.001]
  • [Cites] Endocrinology. 1984 Apr;114(4):1082-5 [6423368.001]
  • [Cites] Endocrinology. 1992 Mar;130(3):1097-102 [1537276.001]
  • [Cites] Clin Endocrinol (Oxf). 1986 Feb;24(2):135-40 [2871948.001]
  • [Cites] Nature. 1983 Nov 3-9;306(5938):84-5 [6415487.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):526-9 [10690849.001]
  • [Cites] Nature. 1985 Mar 21-27;314(6008):279-81 [2858817.001]
  • [Cites] Endocrinology. 1985 Oct;117(4):1598-601 [3928335.001]
  • [Cites] Lancet. 1984 Aug 18;2(8399):401-2 [6147476.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3104-9 [9745411.001]
  • [Cites] Endocrinology. 1983 Nov;113(5):1726-31 [6194979.001]
  • [Cites] Nature. 1993 Jul 15;364(6434):208-13 [8391647.001]
  • [Cites] Eur J Endocrinol. 1995 Jan;132(1):12-24 [7850005.001]
  • [Cites] Am J Clin Pathol. 1986 Jan;85(1):13-20 [3000164.001]
  • [Cites] Eur J Endocrinol. 1998 Jul;139(1):59-71 [9703380.001]
  • [Cites] Clin Endocrinol (Oxf). 1976 Sep;5(5):503-13 [991433.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Sep;87(9):4054-8 [12213843.001]
  • [Cites] Science. 1982 Nov 5;218(4572):585-7 [6812220.001]
  • [Cites] Clin Endocrinol (Oxf). 1989 Apr;30(4):367-77 [2574645.001]
  • [Cites] Endocrinology. 1996 Apr;137(4):1326-31 [8625907.001]
  • [Cites] Endocr Rev. 1986 Aug;7(3):223-53 [2874984.001]
  • [Cites] Am J Med. 1984 Apr;76(4):605-16 [6424465.001]
  • [Cites] Science. 1975 Feb 7;187(4175):447-9 [1111113.001]
  • [Cites] J Clin Endocrinol Metab. 1985 Feb;60(2):370-5 [3917460.001]
  • [Cites] Cancer. 1991 May 15;67(10):2538-42 [2015554.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Oct;128(4):631-2 [15457172.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):575-95 [1521513.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3989-95 [11502843.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Feb;68(2):499-504 [2493033.001]
  • [Cites] Adv Tech Stand Neurosurg. 1995;22:3-53 [7495421.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Oct;59(4):747-51 [6434578.001]
  • [Cites] Annu Rev Med. 1990;41:447-55 [2184742.001]
  • [Cites] J Endocrinol Invest. 1993 Jan;16(1):69-81 [8445159.001]
  • [Cites] Br Med J (Clin Res Ed). 1986 Apr 12;292(6526):981-2 [2870758.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Jan;58(1):212-4 [6417155.001]
  • [Cites] Science. 1985 Oct 25;230(4724):461-3 [2864742.001]
  • [Cites] Mol Endocrinol. 1992 Oct;6(10):1734-44 [1333056.001]
  • [Cites] Eur J Endocrinol. 1997 Jun;136(6):553-65 [9225715.001]
  • [Cites] Ir J Med Sci. 2004 Oct-Dec;173(4):215-6 [16323617.001]
  • [Cites] Acta Endocrinol (Copenh). 1985 May;109(1):13-8 [3923754.001]
  • [Cites] Endocrinology. 1991 Feb;128(2):1151-8 [1671214.001]
  • [Cites] J Endocrinol Invest. 1994 Oct;17(9):717-22 [7868816.001]
  • [Cites] Brain Res. 1989 Feb 27;481(1):8-15 [2565134.001]
  • [Cites] Eur J Endocrinol. 1995 Sep;133(3):320-4 [7581949.001]
  • [Cites] Endocrinology. 1985 Apr;116(4):1334-40 [3918850.001]
  • (PMID = 17036195.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I; 9034-39-3 / Growth Hormone-Releasing Hormone
  • [Number-of-references] 101
  •  go-up   go-down


34. Rice JM: The carcinogenicity of acrylamide. Mutat Res; 2005 Feb 7;580(1-2):3-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In two bioassays in rats, acrylamide administered in drinking water consistently induced peritesticular mesotheliomas, thyroid follicular cell tumors, and mammary gland tumors, as well as primary brain tumors when all such tumors were included in data analysis.
  • In one of the rat bioassays, increased numbers of adrenal pheochromocytomas, adenomas of pituitary and clitoral glands, papillomas of the oral cavity, and adenocarcinomas of the uterus also occurred.
  • Epidemiologic studies of possible health effects from exposures to acrylamide have not produced consistent evidence of increased cancer risk, in either occupationally exposed workers or the general populations of several countries in which acrylamide is present in certain foods and beverages.
  • A doubling of risk for pancreatic cancer was observed in the most highly exposed workers within the largest industrial cohort, but no consistent exposure-response relationships were identified.
  • Retrospective re-analyses of previously conducted case-control studies of cancer incidence in several European populations have identified no causal relationship between consumption of foods or beverages that contain acrylamide and the incidence of cancers at various sites including kidney, large bowel, urinary bladder, oral cavity, pharynx, larynx, esophagus, breast, and ovary.
  • These retrospective studies of cancer incidence in relation to acrylamide in food have limited power to detect increased cancer risks, and have been criticized on various grounds, but they do indicate that no major cancer risks are attributable to intake of acrylamide in Western diets.
  • [MeSH-major] Acrylamide. Carcinogens. Neoplasms / chemically induced. Occupational Exposure / adverse effects
  • [MeSH-minor] Animals. Food Contamination. Humans. Neoplasms, Experimental / chemically induced. Risk

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACRYLAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15668103.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Carcinogens; 20R035KLCI / Acrylamide
  • [Number-of-references] 72
  •  go-up   go-down


35. Owecki M, Majewska KA, Stawny B, Nikisch E, Drews M, Sowiński J: [Adrenal tumours in a selected 10-years surgical material]. Pol Merkur Lekarski; 2006 Jun;20(120):678-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adrenal tumours in a selected 10-years surgical material].
  • The aim of the study was to analyze the number and proportions of different adrenal tumours resected during the last 10 years in our centre.
  • In 45 (65.22%) cases the right adrenal was affected, in 21 (30.43%)--the left, in 3 (4.35%)--both.
  • RESULTS: 12 adrenocortical cancers, 20 phaeochromocytomas, 9 cortisol-secreting adenomas, 4 aldosteronomas, 18 hormonally inactive adenomas, 6 miscellaneous tumours were found.
  • Malignant tumours where significantly larger than benign (12.20 +/- 6.81 vs 6.71 +/- 5.62 cm, p < 0.005).
  • We observed no correlation between the age and preoperative tumor size (p = 0.1756), between the age and pathological tumor size (p = 0.3601), and between BMI and the preoperative and histopathologic size (p = 0.4204, and p = 0.6478, respectively).
  • CONCLUSIONS: The most common tumour was phaeochromocytoma.
  • Most tumours where found in the right adrenal.
  • The malignant tumours where larger than benign ones.
  • No correlations between age and BMI, and tumour size where demonstrated.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007266.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


36. Lodish MB, Stratakis CA: Rare and unusual endocrine cancer syndromes with mutated genes. Semin Oncol; 2010 Dec;37(6):680-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare and unusual endocrine cancer syndromes with mutated genes.
  • The study of a number of rare familial syndromes associated with endocrine tumor development has led to the identification of genes involved in the development of these tumors.
  • Major advances have expanded our understanding of the pathophysiology of these rare endocrine tumors, resulting in the elucidation of causative genes in rare familial diseases and a better understanding of the signaling pathways implicated in endocrine cancers.
  • Recognition of the familial syndrome associated with a particular patient's endocrine tumor has important implications in terms of prognosis, screening of family members, and screening for associated conditions.
  • [MeSH-major] Endocrine Gland Neoplasms / diagnosis. Endocrine Gland Neoplasms / genetics. Neoplastic Syndromes, Hereditary / diagnosis. Neoplastic Syndromes, Hereditary / genetics
  • [MeSH-minor] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / genetics. Carney Complex / diagnosis. Carney Complex / genetics. Hamartoma / diagnosis. Hamartoma / genetics. Humans. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / genetics. Rare Diseases

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3209-15 [16707622.001]
  • [Cites] J Med Genet. 2006 Jun;43(6):523-6 [16155190.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):794-800 [16767104.001]
  • [Cites] Br J Cancer. 2006 Jul 17;95(2):233-8 [16786042.001]
  • [Cites] Orphanet J Rare Dis. 2006;1:21 [16756677.001]
  • [Cites] Am J Med Genet A. 2006 Aug 1;140(15):1669-72 [16835931.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Nov;2(11):632-41 [17082810.001]
  • [Cites] Dis Colon Rectum. 2006 Nov;49(11):1781-90 [17041748.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Apr;92(4):1237-44 [17227804.001]
  • [Cites] Stress. 2007 Jun;10(2):195-203 [17514588.001]
  • [Cites] Horm Metab Res. 2007 Jun;39(6):467-73 [17578766.001]
  • [Cites] N Engl J Med. 2007 Sep 6;357(10):1054-6 [17804857.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Oct;67(4):639-41 [17596199.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2007 Nov;3(11):748-57 [17955016.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):729-32 [18341492.001]
  • [Cites] World J Surg. 2008 Aug;32(8):1815-22 [18521664.001]
  • [Cites] Ann Surg Oncol. 2008 Sep;15(9):2439-50 [18612695.001]
  • [Cites] Expert Opin Pharmacother. 2008 Oct;9(15):2617-26 [18803449.001]
  • [Cites] Ann Oncol. 2008 Oct;19(10):1727-33 [18515795.001]
  • [Cites] Eur J Hum Genet. 2008 Nov;16(11):1289-300 [18781191.001]
  • [Cites] Endocr Pathol. 2008 Winter;19(4):226-40 [18931957.001]
  • [Cites] N Engl J Med. 2009 Jan 8;360(2):195-7 [19129539.001]
  • [Cites] Endocr Relat Cancer. 2009 Mar;16(1):45-58 [18978035.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1250-6 [19204208.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Apr;94(4):1069-73 [19141587.001]
  • [Cites] Lancet Oncol. 2009 May;10(5):508-15 [19410195.001]
  • [Cites] Oncologist. 2009 May;14(5):456-67 [19411317.001]
  • [Cites] J Intern Med. 2009 Jul;266(1):43-52 [19522824.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Sep;94(9):3157-62 [19567519.001]
  • [Cites] Pancreas. 2009 Nov;38(8):876-89 [19855234.001]
  • [Cites] Eur J Hum Genet. 2010 Jan;18(1):8-14 [19550435.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Apr;95(4):1508-15 [20157193.001]
  • [Cites] Eur J Hum Genet. 2008 Jan;16(1):79-88 [17667967.001]
  • [Cites] Front Biosci. 2000 Mar 1;5:D353-66 [10704431.001]
  • [Cites] Nat Cell Biol. 2000 May;2(5):281-7 [10806479.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):89-92 [10973256.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3222-6 [10999812.001]
  • [Cites] J Med Genet. 2000 Nov;37(11):828-30 [11073535.001]
  • [Cites] Hum Mol Genet. 2000 Dec 12;9(20):3037-46 [11115848.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1739-42 [11156460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3387-92 [11248088.001]
  • [Cites] Am J Med Sci. 2001 May;321(5):306-20 [11370794.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4970-3 [11600572.001]
  • [Cites] Am J Med Genet. 2002 Mar 1;108(2):132-9 [11857563.001]
  • [Cites] Am J Epidemiol. 2000 Jan 1;151(1):33-40 [10625171.001]
  • [Cites] Pediatrics. 2000 Mar;105(3 Pt 1):608-14 [10699117.001]
  • [Cites] Endocr Pract. 2002 Mar-Apr;8(2):109-12 [11942775.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;968:75-95 [12119269.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13571-6 [12271141.001]
  • [Cites] Am J Hum Genet. 2002 Dec;71(6):1433-42 [12424709.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):919-32 [12621137.001]
  • [Cites] Lancet. 2003 Apr 19;361(9366):1348-9 [12711473.001]
  • [Cites] Am J Hum Genet. 2003 Jul;73(1):95-106 [12772087.001]
  • [Cites] Hum Mutat. 2003 Sep;22(3):183-98 [12938083.001]
  • [Cites] Mayo Clin Proc. 1999 Jun;74(6):543-52 [10377927.001]
  • [Cites] Am J Surg Pathol. 2003 Oct;27(10):1386-9 [14508401.001]
  • [Cites] Endocr Relat Cancer. 2004 Mar;11(1):1-18 [15027882.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:199-208 [15153435.001]
  • [Cites] J Intern Med. 2004 Aug;256(2):166-73 [15257730.001]
  • [Cites] Minerva Endocrinol. 2004 Mar;29(1):19-24 [15258554.001]
  • [Cites] Pancreatology. 2004;4(5):417-33; discussion 434-5 [15249710.001]
  • [Cites] Ann Intern Med. 1969 Oct;71(4):747-52 [5360287.001]
  • [Cites] Arch Intern Med. 1974 Mar;133(3):492-9 [4359620.001]
  • [Cites] Lancet. 1977 Mar 26;1(8013):666-8 [66472.001]
  • [Cites] J Pediatr. 1978 Sep;93(3):478-80 [211218.001]
  • [Cites] N Engl J Med. 1979 Aug 9;301(6):285-92 [377080.001]
  • [Cites] Gastroenterology. 1980 Dec;79(6):1324-31 [7439637.001]
  • [Cites] Arch Intern Med. 1981 Oct;141(11):1513-5 [7197143.001]
  • [Cites] Fortschr Med. 1982 Oct 21;100(39):1809-12 [7152417.001]
  • [Cites] J Clin Pathol. 1984 Mar;37(3):272-8 [6142060.001]
  • [Cites] Chin Med J (Engl). 1984 Aug;97(8):599-602 [6440749.001]
  • [Cites] Medicine (Baltimore). 1985 Jul;64(4):270-83 [4010501.001]
  • [Cites] Mayo Clin Proc. 1986 Mar;61(3):165-72 [3945116.001]
  • [Cites] N Engl J Med. 1986 Apr 17;314(16):1010-5 [3083258.001]
  • [Cites] World J Surg. 1986 Aug;10(4):586-92 [3019020.001]
  • [Cites] Arch Neurol. 1988 May;45(5):575-8 [3128965.001]
  • [Cites] Hum Genet. 1989 Feb;81(3):273-7 [2921038.001]
  • [Cites] Endocrinol Metab Clin North Am. 1989 Jun;18(2):545-56 [2545444.001]
  • [Cites] Cell. 1990 Jul 13;62(1):193-201 [2114220.001]
  • [Cites] Science. 1990 Jul 13;249(4965):181-6 [2134734.001]
  • [Cites] Cell. 1990 Nov 16;63(4):843-9 [2121370.001]
  • [Cites] Science. 1990 Nov 30;250(4985):1233-8 [1978757.001]
  • [Cites] Ann N Y Acad Sci. 1991;615:125-7 [2039137.001]
  • [Cites] Br J Cancer. 1991 Jun;63(6):993-9 [2069856.001]
  • [Cites] Mayo Clin Proc. 1991 Jul;66(7):711-9 [1677058.001]
  • [Cites] Science. 1991 Aug 9;253(5020):665-9 [1651563.001]
  • [Cites] J Comput Assist Tomogr. 1991 Sep-Oct;15(5):773-9 [1653280.001]
  • [Cites] J Clin Pathol. 1991 Nov;44(11):961-2 [1752991.001]
  • [Cites] J Natl Cancer Inst. 1992 May 6;84(9):703-7 [1569604.001]
  • [Cites] Surgery. 1992 Dec;112(6):1002-8; discussion 1008-9 [1455303.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Dec;55(12):1209 [1479404.001]
  • [Cites] World J Surg. 1993 Jul-Aug;17(4):468-80 [8362529.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1305-15 [8269512.001]
  • [Cites] Zentralbl Pathol. 1994 Feb;139(6):477-81 [8161496.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jun;78(6):1444-53 [7911125.001]
  • [Cites] J Biol Chem. 1995 Jul 7;270(27):16409-14 [7608212.001]
  • [Cites] Ann Intern Med. 1995 Aug 15;123(4):269-73 [7611592.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Aug;16(7):1543-4 [7484652.001]
  • [Cites] J Clin Invest. 1996 Feb 1;97(3):699-705 [8609225.001]
  • [Cites] J Clin Ultrasound. 1997 May;25(4):211-4 [9142622.001]
  • [Cites] JAMA. 1997 Jul 2;278(1):51-7 [9207339.001]
  • [Cites] Gastroenterol Clin Biol. 1997;21(4):343 [9208005.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2037-43 [9215269.001]
  • [Cites] Science. 1997 Aug 8;277(5327):805-8 [9242607.001]
  • [Cites] Dis Colon Rectum. 1997 Sep;40(9):1023-8 [9293929.001]
  • [Cites] J Natl Cancer Inst. 1998 Apr 15;90(8):606-11 [9554443.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2972-6 [9709978.001]
  • [Cites] J Child Neurol. 1998 Dec;13(12):624-8 [9881533.001]
  • [Cites] Eur J Pediatr. 1999 Apr;158(4):284-7 [10206124.001]
  • [Cites] J Child Neurol. 1999 Jun;14(6):401-7 [10385849.001]
  • [Cites] Ann Intern Med. 1999 Oct 19;131(8):585-91 [10523219.001]
  • [Cites] Br Med J. 1959 Nov 21;2(5159):1065-8 [13830461.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3773-9 [15741255.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8573-8 [15937108.001]
  • [Cites] J Histochem Cytochem. 2005 Jul;53(7):895-903 [15995148.001]
  • [Cites] Pediatr Dev Pathol. 2005 May-Jun;8(3):287-304 [16010495.001]
  • [Cites] J Am Acad Dermatol. 2005 Oct;53(4):660-2 [16198789.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):807-17 [16253902.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Dec;63(6):694-5 [16343106.001]
  • (PMID = 21167385.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 HD999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS246989; NLM/ PMC3053053
  •  go-up   go-down


37. Brown KL, Bacal D: Large adrenocortical carcinoma. J Natl Med Assoc; 2009 Dec;101(12):1287-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adrenal cortical carcinomas (ACCs) are rare, highly malignant tumors that carry a poor prognosis.
  • We present a patient who underwent successful resection of a massive 19-cm, nonfunctional ACC, which encased the right kidney.
  • The goal of this report is to enrich the growing body of knowledge concerning the presentation, evaluation, and surgical intervention of these rare cancers.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / surgery
  • [MeSH-minor] Diagnosis, Differential. Diagnostic Imaging. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20070018.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Papewalis C, Kouatchoua C, Wuttke M, Jacobs B, Scherbaum WA, Schott M: Chromogranin a as potential tumour antigen in pheochromocytoma. Horm Metab Res; 2009 Sep;41(9):707-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromogranin a as potential tumour antigen in pheochromocytoma.
  • Importantly, in vitro studies demonstrated the presence of naturally occurring CgA-specific cytotoxic T cells in patients with neuroendocrine cancers.
  • Therefore, it is worthwhile to investigate the potential role of CgA as tumour antigen in pheochromocytoma.
  • [MeSH-major] Adrenal Gland Neoplasms / immunology. Antigens, Neoplasm / immunology. Chromogranin A / immunology. Pheochromocytoma / immunology

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19370504.001).
  • [ISSN] 1439-4286
  • [Journal-full-title] Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme
  • [ISO-abbreviation] Horm. Metab. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Chromogranin A
  • [Number-of-references] 52
  •  go-up   go-down


39. Johnsen JI, Lindskog M, Ponthan F, Pettersen I, Elfman L, Orrego A, Sveinbjörnsson B, Kogner P: NSAIDs in neuroblastoma therapy. Cancer Lett; 2005 Oct 18;228(1-2):195-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • COX-2 is upregulated in several adult epithelial cancers.
  • In neuroblastoma it has been shown that the majority of primary tumours and cell lines express high levels of COX-2, whereas normal adrenal medullas from children do not express COX-2.

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15975708.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase Inhibitors
  • [Number-of-references] 38
  •  go-up   go-down


41. Leboeuf R, Bénard F, Langlois MF: Thyroid cancer presenting as a PET incidentaloma in a patient with concomitant breast cancer metastases to the thyroid. Clin Nucl Med; 2006 Jul;31(7):382-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid cancer presenting as a PET incidentaloma in a patient with concomitant breast cancer metastases to the thyroid.
  • INTRODUCTION: Metastases to the thyroid gland are considered a rare cause of thyroid tumor.
  • CASE DESCRIPTION: We describe the case of a 59-year-old woman who presented with simultaneous papillary and breast carcinoma within the thyroid gland.
  • F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) done for the evaluation of her metastatic breast cancer revealed a thyroid incidentaloma with a high metabolic rate (standardized uptake value [SUV] of 13).
  • CONCLUSION: This is a rare description of a concomitant papillary thyroid carcinoma presenting as an FDG PET incidentaloma alongside breast cancer metastases to the thyroid gland.
  • Thyroid and breast cancer sometimes occur in the same patient.
  • However, no explanation has been found to link these 2 cancers.
  • Although uncommon, FDG PET thyroid incidentalomas seem to harbor a higher rate of malignancy than incidentalomas found on conventional imaging.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Carcinoma, Papillary / radionuclide imaging. Estrogens. Incidental Findings. Neoplasms, Hormone-Dependent / radionuclide imaging. Neoplasms, Hormone-Dependent / secondary. Neoplasms, Second Primary / radionuclide imaging. Positron-Emission Tomography. Thyroid Neoplasms / radionuclide imaging. Thyroid Neoplasms / secondary
  • [MeSH-minor] Adrenal Gland Neoplasms / secondary. Antineoplastic Agents, Hormonal / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Female. Fluorodeoxyglucose F18. Humans. Iodine Radioisotopes / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Mastectomy, Segmental. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / secondary. Middle Aged. Neoplasm Proteins / analysis. Neoplasms, Radiation-Induced / etiology. Neoplasms, Radiation-Induced / radiography. Neoplasms, Radiation-Induced / radionuclide imaging. Radiopharmaceuticals / therapeutic use. Radiotherapy, Adjuvant. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Tamoxifen / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785803.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogens; 0 / Iodine Radioisotopes; 0 / Neoplasm Proteins; 0 / Radiopharmaceuticals; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 094ZI81Y45 / Tamoxifen; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


42. Paliutko IuI, Gakhramanov AD: [Successful surgical treatment of adrenal cancer with repeated metastasis]. Khirurgiia (Mosk); 2008;(12):51-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful surgical treatment of adrenal cancer with repeated metastasis].
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenalectomy / methods. Adrenocortical Carcinoma / secondary. Hepatectomy / methods. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Pneumonectomy / methods
  • [MeSH-minor] Adult. Biopsy. Female. Follow-Up Studies. Humans. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Nephrectomy / methods. Reoperation. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19938263.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


43. Kato M, Higashihara E: [Urological cancer]. Gan To Kagaku Ryoho; 2005 Sep;32(9):1255-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urological cancer].
  • We reported laparoscopic adrenalectomy for adrenal cancer, our experience of laparoscopic partial nephrectomy, radical prostatectomy, retroperitoneal lymph node dissection for testicular cancer.
  • [MeSH-major] Laparoscopy. Lymph Node Excision. Minimally Invasive Surgical Procedures. Urologic Neoplasms / surgery
  • [MeSH-minor] Adrenal Gland Neoplasms / surgery. Adrenalectomy. Female. Humans. Kidney Neoplasms / surgery. Male. Nephrectomy. Prostatectomy. Prostatic Neoplasms / surgery. Testicular Neoplasms / surgery. Urinary Bladder Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184920.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


44. Knüttgen D, Wappler F: [Anaesthesia for patients with adrenal gland diseases]. Anasthesiol Intensivmed Notfallmed Schmerzther; 2007 Mar;42(3):170-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anaesthesia for patients with adrenal gland diseases].
  • [Transliterated title] Anästhesie bei Erkrankungen der Nebennierenrinde--Effizientes Risikomanagement von der Prämedikation bis zum Aufwachraum.
  • Perioperative management of patients with adrenal gland diseases requires detailed information on the individual endocrine status and the potential complications.
  • Addison's disease, after removal of a cortisol producing tumour or as the result of long-term therapy with glucocorticoids) consequent perioperative supplementation of hydrocortisone is mandatory.
  • Removal of a malignant tumour of the adrenal gland may induce massive haemorrhage, and thus anaesthetic management has to be modified.
  • [MeSH-major] Adrenal Gland Diseases / complications. Adrenal Gland Diseases / surgery. Intraoperative Complications / prevention & control

  • Genetic Alliance. consumer health - Adrenal Diseases.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17366436.001).
  • [ISSN] 1439-1074
  • [Journal-full-title] Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS
  • [ISO-abbreviation] Anasthesiol Intensivmed Notfallmed Schmerzther
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Androgens; 0 / Estrogens; 0 / Glucocorticoids; 0 / Mineralocorticoids
  •  go-up   go-down


45. Cekinmez M, Sarica FB, Tufan K, Sener L, Sen O: An unusual cause of low back pain: paravertebral muscle metastases of lung cancer. Neurol Neurochir Pol; 2009 Jan-Feb;43(1):83-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual cause of low back pain: paravertebral muscle metastases of lung cancer.
  • Schwannoma, neurofibroma, ganglioneuroma and paraganglioneuromas that show contiguous spread should also be included in the differential diagnosis.
  • Haematogenous metastases are most frequently caused by lung cancers.
  • Lung cancers typically metastasize to liver, brain, bone, kidney, and adrenal glands.
  • The mass in his lower back region was excised and histopathological examination confirmed metastasis of a neuroendocrine tumour.
  • [MeSH-major] Low Back Pain / etiology. Lung Neoplasms / diagnosis. Muscle Neoplasms / diagnosis. Muscle Neoplasms / secondary. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / secondary

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19353448.001).
  • [ISSN] 0028-3843
  • [Journal-full-title] Neurologia i neurochirurgia polska
  • [ISO-abbreviation] Neurol. Neurochir. Pol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


46. Lee HG, Lee B, Kim SM, Suh BJ, Yu HJ: A case of gastric adenocarcinoma presenting as meningeal carcinomatosis. Korean J Intern Med; 2007 Dec;22(4):304-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leptomeningeal carcinomatosis occurs in approximately 5% of patients with cancer.
  • The most common cancers involving the leptomeninges are breast, lung cancer and melanoma.
  • We report a case of leptomeningeal metastasis that presented as a gastric cancer.
  • The endoscopy showed a thickening of the folds of the stomach compatible with the diagnosis of a Borrman type IV gastric cancer.
  • The cytology examination of the cerebrospinal fluid supported the diagnosis of metastatic signet ring cell carcinoma.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Meningeal Neoplasms / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adrenal Cortex Hormones. Female. Humans. Mannitol. Middle Aged

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. D-MANNITOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3394-402 [10589750.001]
  • [Cites] Am J Clin Oncol. 2003 Apr;26(2):165-70 [12714889.001]
  • [Cites] Jpn J Clin Oncol. 2003 Dec;33(12):608-12 [14769837.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):167-74 [15015782.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):255-60 [16344918.001]
  • [Cites] Neurology. 1999 Jul 22;53(2):382-5 [10430430.001]
  • [Cites] J Neurooncol. 1999 May;43(1):59-62 [10448872.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2005 May;17(5):577-9 [15827450.001]
  • [Cites] J Clin Neurosci. 2005 Apr;12(3):315-8 [15851093.001]
  • [Cites] Ann Oncol. 2004;15 Suppl 4:iv285-91 [15477323.001]
  • (PMID = 18309694.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 3OWL53L36A / Mannitol
  • [Other-IDs] NLM/ PMC2687665
  •  go-up   go-down


47. Bertherat J, Bertagna X: Pathogenesis of adrenocortical cancer. Best Pract Res Clin Endocrinol Metab; 2009 Apr;23(2):261-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenesis of adrenocortical cancer.
  • The study of the clonality of adrenocortical tumours (ACTs) has shown that adrenocortical cancers (ACCs) are of monoclonal origin.
  • Somatic mutations of the tumour suppressor gene TP53 are observed in a third of ACCs.
  • This recent progress in the molecular genetics of ACC has led to the development of new molecular markers for the diagnosis of malignancy; these might also help to identify prognostic markers of ACC and may ultimately lead to novel therapeutic approaches.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19500768.001).
  • [ISSN] 1878-1594
  • [Journal-full-title] Best practice & research. Clinical endocrinology & metabolism
  • [ISO-abbreviation] Best Pract. Res. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 67
  •  go-up   go-down


48. Nahleh Z: Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory. Future Oncol; 2008 Feb;4(1):15-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory.
  • Estrogen receptor-negative (ER-) and progesterone receptor-negative (PR-) breast cancers represent approximately 30% of all breast cancers and, in general, have a more aggressive clinical course.
  • Androgen receptor (AR) expression has been reported in over 70% of breast cancer and in 45-50% of patients with ER-negative breast cancer.
  • Preclinical data have suggested the inhibitory role of adrenal steroids, such as dehydroepiandosterone (DHEA) and its sulfate on the growth of human ER-negative breast cancer cell lines, when these demonstrate a strong expression of AR.
  • However, DHEA has been shown to stimulate growth in breast cancer cells when an ER is expressed in ER-positive breast cancer cells.
  • Therefore, the effect of adrenal steroids may differ based on the tumor hormone receptor status and ER-/PR- breast tumors may not be truly hormone 'insensitive'.
  • This article reviews the role of the AR in breast cancer and discusses potential avenues for the treatment of ER-/PR-/AR+ tumors with 'hormonal therapy'.
  • [MeSH-major] Androgen Receptor Antagonists. Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Dehydroepiandrosterone / therapeutic use
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Humans. Receptors, Androgen / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18240997.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Receptor Antagonists; 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Receptors, Androgen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 459AG36T1B / Dehydroepiandrosterone
  • [Number-of-references] 51
  •  go-up   go-down


49. Labrie F: [Keyrole of endocrinology in the victory against prostate cancer]. Bull Cancer; 2006 Sep;93(9):949-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Keyrole of endocrinology in the victory against prostate cancer].
  • [Transliterated title] Rôle clé de l'endocrinologie dans la victoire contre le cancer de la prostate.
  • The most significant discovery of the last quarter of the XXth century in the field of prostate cancer is probably the observation that the human prostate synthesizes locally an amount of androgens from the inactive steroid precursors dehydroepiandrosterone (DHEA) and its sulfate DHEA-S that is approximately equivalent to the androgens made in the testis.
  • This treatment, called combined androgen blockade, has been the first treatment demonstrated to prolong life in prostate cancer in prospective and randomized studies.
  • While the first studies were performed in patients with advanced and metastatic disease, our recent data indicate a much higher efficacy of the same treatment applied to localized prostate cancer, thus leading to an at least 90 % possibility of cure.
  • In fact, the lifesaving benefits of androgen blockade in prostate cancer have been largely underestimated.
  • When compared to other cancer therapies, the results obtained are quite remarkable.
  • In fact, while death rates decreased by 1.1 % per year from 1993 to 2001 for all cancers combined, prostate cancer showed a larger decrease at 3.6 %.
  • Lichtenberg using National Cancer Institute data obtained from 2.1 million cancer patients, has concluded that "cancer-fighting drugs improved survival rates, especially for cancer of the prostate, where drug innovations have been the greatest".
  • The knowledge about the absence of development of resistance to androgen blockade in localized prostate cancer is extremely important.
  • In fact, deferring treatment implies that, very often, it will then be too late, because after the cancer has migrated to the bones, resistance to treatment can no more be avoided.
  • It should be realized that when prostate cancer is first detected, even by screening, the cancer is not small since its diameter is of the order of 1 cm or more.
  • This is the most appropriate time to treat with the strong hope of a cure.
  • With the presently available techniques, screening can diagnose prostate cancer at a clinically localized stage in 99 % of cases.
  • Such an early diagnosis permits immediate treatment with a curative intent, combined androgen blockade (CAB) being a truly efficient alternative especially in older patients.
  • Using this strategy, based upon today's available diagnostic and therapeutic approaches, death from prostate cancer can be an exception, confirming that victory against prostate cancer is achieved.
  • [MeSH-major] Gonadotropin-Releasing Hormone / agonists. Neoplasms, Hormone-Dependent / therapy. Prostatic Neoplasms / therapy
  • [MeSH-minor] Adrenal Glands / metabolism. Androgen Antagonists / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Dehydroepiandrosterone / antagonists & inhibitors. Dehydroepiandrosterone / metabolism. Flutamide / therapeutic use. Humans. Male. Orchiectomy. Prostatectomy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980238.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; 33515-09-2 / Gonadotropin-Releasing Hormone; 459AG36T1B / Dehydroepiandrosterone; 76W6J0943E / Flutamide
  • [Number-of-references] 30
  •  go-up   go-down


50. Fujiwara M, Kamma H, Wu W, Yano Y, Homma S, Satoh H: Alternative lengthening of telomeres in the human adrenocortical carcinoma cell line H295R. Int J Oncol; 2006 Aug;29(2):445-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The biological significance and molecular mechanism of ALT have not been well studied in human cancers.
  • We anticipate that H295R cells will be a good model for understanding the significance and mechanism of ALT in human cancers.
  • [MeSH-major] Adrenal Cortex Neoplasms / ultrastructure. Carcinoma / ultrastructure. Telomere / ultrastructure
  • [MeSH-minor] Cell Line, Tumor. Cell Nucleus / metabolism. HeLa Cells. Humans. In Situ Hybridization, Fluorescence. Neoplasms / metabolism. Oligonucleotides / chemistry. Phenotype. Reverse Transcriptase Polymerase Chain Reaction. Telomerase / metabolism

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820888.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Oligonucleotides; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


51. Waalkes MP, Liu J, Ward JM, Powell DA, Diwan BA: Urogenital carcinogenesis in female CD1 mice induced by in utero arsenic exposure is exacerbated by postnatal diethylstilbestrol treatment. Cancer Res; 2006 Feb 1;66(3):1337-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arsenic alone induced some urogenital system tumors, including mostly benign tumors of the ovary and uterus, and adrenal adenoma.
  • Diethylstilbestrol alone induced some tumors (primarily cervical) but when given after in utero arsenic, it greatly enhanced urogenital tumor incidence, multiplicity, and progression.
  • For instance, compared with the incidence of urogenital malignancies in the control (0%), arsenic alone (9%), and diethylstilbestrol alone (21%) groups, arsenic plus diethylstilbestrol acted synergistically, inducing a 48% incidence of malignant urogenital tumors.
  • Of the urogenital tumors induced by arsenic plus diethylstilbestrol, 80% were malignant, and 55% were multiple site.
  • Tamoxifen alone did not increase urogenital tumors or affect arsenic-induced neoplasia but did increase arsenic-induced uroepithelial proliferative lesions.
  • Thus, arsenic acts with estrogens to enhance production of female mouse urogenital cancers.
  • [MeSH-major] Arsenic / toxicity. Diethylstilbestrol / toxicity. Genital Neoplasms, Female / chemically induced. Kidney Neoplasms / chemically induced. Prenatal Exposure Delayed Effects. Urinary Bladder Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452187.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01 CO 12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 094ZI81Y45 / Tamoxifen; 731DCA35BT / Diethylstilbestrol; N712M78A8G / Arsenic
  •  go-up   go-down


52. Clark HA, Snedeker SM: Critical evaluation of the cancer risk of dibromochloropropane (DBCP). J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2005;23(2):215-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical evaluation of the cancer risk of dibromochloropropane (DBCP).
  • Dibromochloropropane (1,2-dibromo-3-chloropropane, DBCP), a pesticide used widely for over 20 years to control nematodes on crops, turf and in nurseries, was banned by the United States Environmental Protection Agency (US EPA) in 1977 because of evidence of infertility in men and induction of a variety of tumors in laboratory animals.
  • In this review, we present a critical evaluation of the available scientific literature on the potential for DBCP to affect cancer risk, including the results of animal cancer bioassays, human epidemiological studies and in vitro and in vivo genotoxicity studies.
  • Results from long-term cancer bioassays in rodents show a statistically significant increase in the incidence of malignant and benign mammary gland tumors in female rats treated orally with DBCP compared to controls and some evidence of increased incidence of mammary fibroadenomas in DBCP low-dose treated female rats exposed by inhalation.
  • Rats exposed to DBCP by inhalation showed significant increases in tumors of the tunica vaginalis in males; tumors of the pharynx and adrenal gland in females; and tumors of the tongue, nasal turbinate and nasal cavity in both sexes compared to controls.
  • Male and female mice exposed to DBCP by inhalation experienced increased tumor incidence in the lungs and nasal cavity compared to controls.
  • Although high mortality rates in both rat and mouse bioassays limited the ability to detect tumors late in life, the induction of a variety of tumors by multiple routes of exposure in two rodent species provides clear evidence of a DBCP tumorigenic response.
  • Few studies have been conducted to assess whether DBCP workplace or drinking water exposures affect cancer risk in humans.
  • While case-control, cohort and ecological epidemiology studies have not found significant, positive associations between DBCP exposure and cancer in exposed populations, these studies have numerous limitations including small numbers of participants, a lack of control for confounding factors, lack of exposure information on DBCP and other chemicals and short follow-up times.
  • Given the persistent nature of DBCP contamination in areas of past use, efforts should be made to continue remediation efforts and follow previously exposed populations for development of certain human cancers, including breast, ovarian, stomach, respiratory, oral and nasal cancers, among others.
  • [MeSH-major] Antinematodal Agents / toxicity. Neoplasms / chemically induced. Propane / analogs & derivatives

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROPANE .
  • Hazardous Substances Data Bank. 1,2-DIBROMO-3-CHLOROPROPANE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16291528.001).
  • [ISSN] 1059-0501
  • [Journal-full-title] Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews
  • [ISO-abbreviation] J Environ Sci Health C Environ Carcinog Ecotoxicol Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antinematodal Agents; 0 / Carcinogens; 0 / Environmental Pollutants; 96K0FD4803 / 1,2-dibromo-3-chloropropane; T75W9911L6 / Propane
  • [Number-of-references] 118
  •  go-up   go-down


53. Ramírez Plaza CP, Santoyo Santoyo J, Domínguez López ME, Eloy-García Carrasco C, Cobo Dols M, Suárez Muñoz MA, Fernández Aguilar JL, de la Fuente Perucho A: [Adrenal carcinoma: 7 year disease free survival after complete primary tumor resection and repeated resection of local-regional and distant recurrences. Review after one case with poor initial life expectancy]. Arch Esp Urol; 2005 Mar;58(2):115-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adrenal carcinoma: 7 year disease free survival after complete primary tumor resection and repeated resection of local-regional and distant recurrences. Review after one case with poor initial life expectancy].
  • [Transliterated title] Carcinoma suprarrenal: supervivencia a 7 años libre de enfermedad tras resección completa del tumor primario y resecciones repetidas de recidivas locorregional y a distancia. Revisión a raiz de un caso con una pobre esperanza de vida inicial.
  • OBJECTIVES: We report the case of a female patient with adrenal carcinoma who had undergone surgery and presented with local-regional and distant recurrences, emphasizing the importance of the aggressive surgical treatment to achieve long-term survival which is unexpected sometimes.
  • METHODS/RESULTS: We report the case of a 29-year-old female patient who consulted for left flank pain, being diagnosed of an adrenal tumor by radiological tests; she underwent surgical excision of a left adrenal carcinoma (stage II).
  • Currently, the patient is alive and free of disease 7 years after diagnosis.
  • CONCLUSIONS: Adrenal cancer recurrences have been considered lethal in the short-term.
  • Nevertheless, an aggressive surgical approach of local recurrences and metastasic disease may significantly prolong patient's survival and, sometimes, leave the patient disease free several years after the diagnosis of the primary tumor.
  • [MeSH-major] Adrenal Gland Neoplasms / surgery. Carcinoma / surgery

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15847268.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


54. Nagase H, Yokouchi H, Ide Y, Okada K, Yanagisawa T, Mukai R, Ota H, Maruyama K, Murata K, Kinuta M: [The case of a person who was revealed by adrenal metastasis of pulmonary pleomorphic carcinoma]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2747-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The case of a person who was revealed by adrenal metastasis of pulmonary pleomorphic carcinoma].
  • Computed tomography revealed a tumor of right adrenal gland and a tumor of upper lobe of the right lung.
  • Adrenal tumor had rapidly increased, so we performed adrenectomy.
  • At first adrenal tumor was diagnosed as primary adrenal cancer because its histological findings did not coincide with those of common histologic types of lung cancer.
  • As there were possibilities that one of adrenal or lung tumor was primary and the other was metastatic or both of the two were double primary, we performed right upper lobectomy.
  • Lung tumor was diagnosed as primary pleomorphic carcinoma containing spindle-shaped tumor cells and adenocarcinoma, and then the diagnosis of adrenal tumor was corrected as metastasis of lung cancer.
  • Two months after the lung operation, cervical lymph node swelling, metastasis of stomach and local recurrence of adrenal tumor appeared.
  • [MeSH-major] Adenocarcinoma / pathology. Adrenal Gland Neoplasms / secondary. Lung Neoplasms / pathology
  • [MeSH-minor] Adrenalectomy. Humans. Male. Middle Aged. Neoplasms, Unknown Primary / diagnosis. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224700.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


55. Mokos I, Bernat MM, Mareković Z, Pasini J: Virilizing adrenal cancer and bail-out nephrectomy. Coll Antropol; 2005 Dec;29(2):753-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Virilizing adrenal cancer and bail-out nephrectomy.
  • We report a rare case of virilizing adrenal cancer with tumorous invasion of the left renal vein in which a retroperitoneal adrenalectomy with bail-out nephrectomy was performed.
  • A tumor thrombus infiltrated the wall of the left adrenal vein and extended into the left renal vein.
  • Initially, a kidney sparing procedure with partial tangential excision of the involved renal vein wall was performed.
  • To the authors' awareness, this is the first report of a virilizing adrenal cancer with a tumor thrombus infiltration of the renal vein and surgical tendency for kidney preservation.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenal Cortex Neoplasms / surgery. Adrenalectomy. Neoplastic Cells, Circulating / pathology. Nephrectomy. Renal Veins / pathology. Virilism / etiology

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16417195.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


61. Narimoto K, Mizokami A, Izumi K, Mihara S, Sawada K, Sugata T, Shimamura M, Miyazaki K, Nishino A, Namiki M: Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen. Int J Urol; 2010 Apr;17(4):337-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
  • OBJECTIVES: To analyze the clinical effects of flutamide as a second-line anti-androgen for combined androgen blockade in patients with castration-resistant prostate cancer (CRPC) initially treated with bicalutamide as a first-line anti-androgen.
  • Furthermore, adrenal androgen levels in a medium of adrenal cancer cell line were also measured.
  • In vitro, 3 micromol/L flutamide suppressed DHEA, androstenedione and androstenediol synthesis compared with bicalutamide in a medium of adrenal cancer cell line.
  • CONCLUSIONS: Our data show that flutamide suppresses the adrenal androgens in comparison with bicalutamide.
  • Metabolites from adrenal androgens contribute to the progression of prostate cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Androgens / blood. Flutamide / therapeutic use. Prostate-Specific Antigen / blood. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Adrenal Glands / secretion. Aged. Aged, 80 and over. Cell Line, Tumor. Humans. Male. Orchiectomy. Prognosis. Salvage Therapy


62. Espina AG, Méndez-Vidal C, Moreno-Mateos MA, Sáez C, Romero-Franco A, Japón MA, Pintor-Toro JA: Induction of Dlk1 by PTTG1 inhibits adipocyte differentiation and correlates with malignant transformation. Mol Biol Cell; 2009 Jul;20(14):3353-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of Dlk1 by PTTG1 inhibits adipocyte differentiation and correlates with malignant transformation.
  • Pituitary tumor-transforming gene-1 (PTTG1) is an oncogene highly expressed in a variety of endocrine, as well as nonendocrine-related cancers.
  • Dlk1 is known to participate in several differentiation processes, including adipogenesis, adrenal gland development, and wound healing.
  • [MeSH-major] Adipocytes / cytology. Cell Differentiation. Cell Transformation, Neoplastic / pathology. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. Membrane Proteins / genetics. Neoplasm Proteins / metabolism

  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2005 Oct;37(10):1047-54 [16142232.001]
  • [Cites] Mol Cell Biol. 1997 Feb;17(2):977-88 [9001251.001]
  • [Cites] Oncogene. 2006 Mar 23;25(13):1852-61 [16288219.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Apr;91(4):1404-9 [16418208.001]
  • [Cites] Int J Oncol. 2006 Aug;29(2):387-95 [16820881.001]
  • [Cites] Nat Med. 2006 Aug;12(8):925-32 [16892036.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]
  • [Cites] Traffic. 2007 Aug;8(8):959-69 [17547700.001]
  • [Cites] J Mol Biol. 2007 Aug 17;371(3):585-95 [17586524.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5596-605 [17353909.001]
  • [Cites] Cell Death Differ. 2008 Jan;15(1):202-12 [17962814.001]
  • [Cites] Nucleic Acids Res. 2008 Feb;36(3):826-38 [18084024.001]
  • [Cites] Lancet. 2000 Feb 26;355(9205):716-9 [10703804.001]
  • [Cites] Med Pediatr Oncol. 2000 Dec;35(6):554-8 [11107116.001]
  • [Cites] Nucleic Acids Res. 2001 Mar 15;29(6):1300-7 [11238996.001]
  • [Cites] Cell. 2001 May 18;105(4):445-57 [11371342.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):8484-91 [11115508.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):109-17 [11905802.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Oncogene. 1998 Oct 29;17(17):2187-93 [9811450.001]
  • [Cites] J Biol Chem. 1998 Nov 27;273(48):31751-8 [9822638.001]
  • [Cites] J Biol Chem. 1999 Apr 30;274(18):12632-41 [10212243.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Oncogene. 1999 Sep 23;18(39):5473-6 [10498901.001]
  • [Cites] Jpn J Clin Oncol. 2002 Jul;32(7):233-7 [12324572.001]
  • [Cites] Nat Genet. 2002 Oct;32(2):306-11 [12355087.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Eur J Endocrinol. 2003 Feb;148(2):203-11 [12590639.001]
  • [Cites] J Clin Invest. 2003 Aug;112(3):345-56 [12865419.001]
  • [Cites] Nucleic Acids Res. 1991 Sep 11;19(17):4647-53 [1891356.001]
  • [Cites] Science. 1992 Aug 14;257(5072):967-71 [1354393.001]
  • [Cites] J Biol Chem. 1993 Feb 25;268(6):3817-20 [8095043.001]
  • [Cites] Cell. 1993 May 21;73(4):725-34 [8500166.001]
  • [Cites] Biotechniques. 1996 Aug;21(2):292-6 [8862815.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Feb 17;340(3):995-1005 [16403460.001]
  • (PMID = 19477929.001).
  • [ISSN] 1939-4586
  • [Journal-full-title] Molecular biology of the cell
  • [ISO-abbreviation] Mol. Biol. Cell
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DLK1 protein, human; 0 / Dlk1 protein, mouse; 0 / Foxa2 protein, mouse; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human; 135845-92-0 / Hepatocyte Nuclear Factor 3-beta
  • [Other-IDs] NLM/ PMC2710844
  •  go-up   go-down


63. Cai C, Zhang HY, Le JJ, Dong JC, Cui Y, Xu CQ, Liu BJ, Wu JF, Duan XH, Cao YX: Inflammatory airway features and hypothalamic-pituitary-adrenal axis function in asthmatic rats combined with chronic obstructive pulmonary disease. Chin Med J (Engl); 2010 Jul;123(13):1720-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory airway features and hypothalamic-pituitary-adrenal axis function in asthmatic rats combined with chronic obstructive pulmonary disease.
  • This study was to evaluate changes of inflammatory airway features and hypothalamic-pituitary-adrenal (HPA) axis function in asthmatic rats combined with COPD.
  • [MeSH-major] Asthma / immunology. Asthma / pathology. Hypothalamo-Hypophyseal System / pathology. Inflammation / physiopathology. Pituitary-Adrenal System / pathology. Pulmonary Disease, Chronic Obstructive / immunology

  • MedlinePlus Health Information. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - COPD.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20819636.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 9015-71-8 / Corticotropin-Releasing Hormone
  •  go-up   go-down


64. Stratakis CA: Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome). Endocr Dev; 2008;13:117-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endogenous Cushing syndrome (CS) is caused by excess adrenal glucocorticoid secretion that is adrenocorticotropin (ACTH)-dependent or independent; ACTH-independent adrenocortical causes of CS account for up to 20% of CS in adults, and 15% in children over age 7 years.
  • In both adults and children, adrenocortical lesions causing CS include the common, isolated and sporadic, solitary cortisol-producing adenoma, the rare adrenocortical cancer, and a spectrum of recently recognized, bilateral hyperplasias (bilateral adrenocortical hyperplasias, BAHs): micronodular adrenal disease and its pigmented variant, primary pigmented nodular adrenocortical disease are mostly genetic processes.
  • The majority of benign adrenocortical tumors associated with CS are associated with defects of the cAMP signaling pathway, whereas adrenal cancer is linked to aberrant expression of growth factors and germline or somatic mutations of tumor suppressor genes such as TP53.
  • [MeSH-major] Adenoma / complications. Adrenal Cortex Neoplasms / complications. Adrenal Glands / pathology. Adrenocorticotropic Hormone / physiology. Cushing Syndrome / etiology
  • [MeSH-minor] Algorithms. Cyclic AMP / physiology. Humans. Hyperplasia / complications. Hyperplasia / diagnosis. Hyperplasia / genetics. Signal Transduction / physiology

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Corticotropin .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. KEGG: Data: Disease Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1163-7 [9543134.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Apr;82(4):1274-8 [9100606.001]
  • [Cites] Endocr Rev. 1998 Oct;19(5):647-72 [9793762.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Mar;84(3):1122-8 [10084605.001]
  • [Cites] Ann Intern Med. 1999 Oct 19;131(8):585-91 [10523219.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):794-800 [16767104.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11571-5 [17178847.001]
  • [Cites] Endocr Relat Cancer. 2007 Mar;14(1):13-28 [17395972.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2372-80 [17554118.001]
  • [Cites] N Engl J Med. 2007 Jun 7;356(23):2415-8 [17554125.001]
  • [Cites] Pediatrics. 2007 Sep;120(3):e575-86 [17698579.001]
  • [Cites] Curr Opin Endocrinol Diabetes Obes. 2007 Jun;14(3):219-25 [17940443.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2007 Nov;3(11):748-57 [17955016.001]
  • [Cites] Surgery. 2007 Dec;142(6):1011-21; discussion 1011-21 [18063089.001]
  • [Cites] N Engl J Med. 2008 Feb 14;358(7):750-2 [18272904.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):89-92 [10973256.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3262-5 [10999819.001]
  • [Cites] Lancet. 2001 Mar 10;357(9258):783-91 [11253984.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9330-5 [11481490.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4041-6 [11549623.001]
  • [Cites] Ann N Y Acad Sci. 2002 Sep;970:112-8 [12381546.001]
  • [Cites] Ann Intern Med. 2003 Mar 4;138(5):424-9 [12614096.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Aug;88(8):3931-7 [12915689.001]
  • [Cites] Trends Endocrinol Metab. 2003 Nov;14(9):404-10 [14580759.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Mar;60(3):273-87 [15008991.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3173-82 [15240590.001]
  • [Cites] J Pediatr Surg. 1971 Apr;6(2):169-75 [4325361.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Feb;78(2):418-22 [8106630.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Nov;77(5):1308-12 [8077325.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Oct;79(4):1082-5 [7962277.001]
  • [Cites] N Engl J Med. 1995 Mar 23;332(12):791-803 [7862184.001]
  • [Cites] Horm Metab Res. 1998 Jun-Jul;30(6-7):456-63 [9694579.001]
  • (PMID = 18493137.001).
  • [ISSN] 1421-7082
  • [Journal-full-title] Endocrine development
  • [ISO-abbreviation] Endocr Dev
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 HD000642-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone; E0399OZS9N / Cyclic AMP
  • [Number-of-references] 33
  • [Other-IDs] NLM/ NIHMS307822; NLM/ PMC3132884
  •  go-up   go-down


65. Mezhir JJ, Song J, Piano G, Testa G, Raman J, Al-Ahmadie HA, Angelos P: Adrenocortical carcinoma invading the inferior vena cava: case report and literature review. Endocr Pract; 2008 Sep;14(6):721-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To present the case of a man with a right-sided adrenocortical carcinoma that invaded the inferior vena cava and was managed by radical resection and vein patch repair.
  • RESULTS: In a 34-year-old man with new-onset abdominal pain, abdominal imaging disclosed a large right adrenal mass with invasion into the inferior vena cava.
  • Laboratory values revealed that the adrenal mass was likely nonfunctional.
  • At surgical intervention with use of cardiopulmonary bypass, the mass was removed en bloc with the adrenal gland, right kidney, and the wall of the inferior vena cava, and the inferior vena cava was reconstructed with bovine pericardium.
  • CONCLUSION: Despite direct invasion or extension of tumor thrombus into the inferior vena cava (or both), complete (R0) resection can be obtained.
  • Thus, this scenario should not preclude attempted curative resection in patients with adrenal cancer.
  • [MeSH-major] Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / pathology. Vena Cava, Inferior / pathology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18996792.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


66. Kouidou S, Malousi A, Kyventidis A, Fragou A, Maglaveras N: G:C &gt; A:T mutations and potential epigenetic regulation of p53 in breast cancer. Breast Cancer Res Treat; 2007 Dec;106(3):351-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] G:C > A:T mutations and potential epigenetic regulation of p53 in breast cancer.
  • Analysis of germline p53 mutations in breast cancer reveals that the Li-Fraumeni and Li-Fraumeni-like syndromes are mostly related to the loss of initiation codon 133 of regulatory TP53 isoforms (Delta133p53).
  • In eight codons of exons 5-8 (including 133), mutations are frequent in Li-Fraumeni-related, but scarce in sporadic breast cancer, while in six more codons they are frequent both in familial and sporadic breast cancers.
  • At the proximity of these codons, we observed in somatic mutation databases, 16 codons (minihotspots mostly in exons 7, 8) which undergo frequent G:C > A:T transitions (non-CpG) in all sporadic cancers.
  • In addition, in sporadic breast cancer we observed 35 adjacent codons in which the following types of mutation are observed: frequent G:C > A:T transitions at CCs/GGs, frequent silent mutations in exons 5,6 and suppressed nonsense mutations (5 codons, few records).
  • Non-CpG G:C > A:T transitions in the 35 codons are rare in familial cancers (p53, BRCA1, or BRCA2-related), but frequent in sporadic cancers in organs where Li-Fraumeni-related carcinogenesis is common e.g. adrenal cortex, soft tissues.
  • These data are in support of the following tissue-specific processes: in sporadic breast cancer (sarcomas etc.
  • Frequent C > T activation at non-CpG is also observed in prostate sporadic cancer, which similarly to breast, undergoes age-related crisis.
  • [MeSH-major] Breast Neoplasms / genetics. Epigenesis, Genetic. Genes, p53. Mutation
  • [MeSH-minor] Codon. CpG Islands. Female. Humans. Ovarian Neoplasms / genetics


67. Michael McClain R, Wolz E, Davidovich A, Pfannkuch F, Edwards JA, Bausch J: Acute, subchronic and chronic safety studies with genistein in rats. Food Chem Toxicol; 2006 Jan;44(1):56-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There is wide spread interest in phytoestrogens as chemopreventive agents for a variety of diseases and cancers based on epidemiologic evidence.
  • For clinical chemistry, with the exception of a slight increase in gamma glutamyl transferase in male and female rats at the high dose, there were a number of other minor changes considered not toxicologically significant.
  • Organ weight changes in male rats at the high dose of 500 mg/kg/day included increased kidney, spleen, adrenal and testes weights and for females included, increased liver, kidney, spleen, ovary and uterus weights.
  • The increased incidence of minimal bile duct proliferation and slightly increased gamma glutamyl transferase are indicative of a mild hepatic effect at the high dose of 500 mg/kg/day.

  • Hazardous Substances Data Bank. GENISTEIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16213646.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Phytoestrogens; DH2M523P0H / Genistein; EC 2.3.2.2 / gamma-Glutamyltransferase
  •  go-up   go-down


68. Sidhu S, Martin E, Gicquel C, Melki J, Clark SJ, Campbell P, Magarey CJ, Schulte KM, Röher HD, Delbridge L, Robinson BG: Mutation and methylation analysis of TP53 in adrenal carcinogenesis. Eur J Surg Oncol; 2005 Jun;31(5):549-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation and methylation analysis of TP53 in adrenal carcinogenesis.
  • AIM: To investigate the role of coding region mutation and promoter hypermethylation of TP53 in adrenocortical cancer formation.
  • METHODS: Twenty sporadic adrenocortical cancers (ACCs) and five normal adrenal tissue samples were available for analysis.
  • In 10 ACCs and five normal adrenal tissue specimens, methylation of the 16 CpG sites within the TP53 promoter was examined using bisulphite methylation sequencing.
  • Four of 5 patients with a TP53 mutation had metastases at diagnosis or detected soon thereafter and 3 of 4 died of disease within 12 months of surgical resection.
  • No methylation was seen in the TP53 promoter in 10 ACC and the five normal adrenal tissues examined.
  • Promoter methylation of TP53 is not present in ACC as a mechanism for tumour suppressor gene (TSG) inactivation and, therefore, other genes in the 17p13 region are implicated in adrenal carcinogenesis.
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Adrenal Gland Neoplasms / metabolism. DNA Methylation. Genes, p53. Mutation. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15922892.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


69. Butler C, Butler WM, Rizvi AA: Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. Endocr Pract; 2010 May-Jun;16(3):441-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An 8-cm left adrenal lesion was found on computed tomography, removed surgically, and confirmed as adrenal carcinoma on pathologic examination.
  • CONCLUSION: Multiple kinase inhibitors such as sorafenib provide targeted oncologic treatment and may be effective in treating advanced adrenal cancer.

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061282.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


70. Otsuki H, Ito K, Kosaka T, Mikami H, Yoshii H, Asakuma J, Kaji T, Asano T, Hayakawa M: [Adrenal metastasis of lung adenocarcinoma with unusual sites of lymph node metastasis and concomitant renal cell carcinoma: a case report]. Hinyokika Kiyo; 2007 Dec;53(12):879-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adrenal metastasis of lung adenocarcinoma with unusual sites of lymph node metastasis and concomitant renal cell carcinoma: a case report].
  • Right adrenal tumor was found by computed tomography and he was referred to our hospital.
  • Imaging studies revealed right adrenal tumor (8 cm) with marked swelling of surrounding lymph nodes and synchronous left renal tumor (2 cm) that was weakly enhanced by contrast media.
  • Needle biopsy of the left kidney proved to be clear cell type renal cell carcinoma (RCC) and the preoperative diagnosis was left RCC and right primary adrenal cancer with lymph node metastasis.
  • Pathological findings of right adrenal tumor and lymph nodes were both metastatic adenocarcinoma, which was not consistent with RCC or adrenal-derived carcinoma.
  • According to pathological findings and an elevation of carcinoembryogenic antigen, the adrenal lesion was diagnosed as adrenal metastasis of lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adrenal Gland Neoplasms / secondary. Carcinoma, Renal Cell / complications. Kidney Neoplasms / complications. Lung Neoplasms / pathology. Lymphatic Metastasis / pathology. Neoplasms, Multiple Primary


71. Schteingart DE, Benitez R, Bradford C, Narayan A, Wang S: Expression of anti-apoptosis genes determines the response of adrenal cancer to apoptosis-inducing chemotherapy. Anticancer Res; 2010 Dec;30(12):4805-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of anti-apoptosis genes determines the response of adrenal cancer to apoptosis-inducing chemotherapy.
  • BACKGROUND: This study tested the hypothesis that response of adrenal cortical carcinoma (ACC) to pro-apoptosis drugs depends on expression of anti-apoptosis genes.
  • MATERIALS AND METHODS: Expression of Bcl-2 and Bcl-XL proteins was determined in two human adrenal cancer cell lines, NCI-H-295 and RL-251.
  • Profiling adrenal tumors for expression of anti-apoptosis genes may provide clues to their potential response to drugs that induce apoptosis.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenal Cortex Neoplasms / genetics. Apoptosis / drug effects. Apoptosis / genetics. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. bcl-X Protein / biosynthesis
  • [MeSH-minor] Animals. Cell Line, Tumor. Genes, bcl-2. Gossypol / pharmacology. Humans. Mice. Mice, SCID. Taxoids / pharmacology

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Gossypol .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187456.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Taxoids; 0 / bcl-X Protein; 15H5577CQD / docetaxel; KAV15B369O / Gossypol
  •  go-up   go-down


72. Khochikar MV: Management of urological cancers during pregnancy. Nat Rev Urol; 2010 Apr;7(4):195-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of urological cancers during pregnancy.
  • Urological cancers during pregnancy pose many challenges for clinicians.
  • As these tumors are very rare among pregnant women and their symptoms might mimic those of common pregnancy-related disorders, the diagnosis is often delayed.
  • Once a urological tumor is diagnosed in a pregnant patient, appropriate steps should be taken to treat her and the fetus at the same time.
  • Common urological cancers that might occur during pregnancy include renal cancer, bladder cancer and adrenal tumors, particularly pheochromocytoma.
  • The treatment outcomes of these cancers in pregnant women are no different from those in the general population.
  • [MeSH-major] Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / surgery. Urologic Neoplasms / diagnosis. Urologic Neoplasms / surgery

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Rev Urol. 2010 Jul;7(7):doi:10.1038/nrurol.2010.25-c1 [20665982.001]
  • (PMID = 20212515.001).
  • [ISSN] 1759-4820
  • [Journal-full-title] Nature reviews. Urology
  • [ISO-abbreviation] Nat Rev Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 85
  •  go-up   go-down


73. Warne GL: Long-term outcome of disorders of sex development. Sex Dev; 2008;2(4-5):268-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many studies have focused on a particular disorder and there have been more about congenital adrenal hyperplasia and complete androgen insensitivity (CAIS) than any of the other conditions, even though mixed gonadal dysgenesis is probably more common than CAIS.
  • The studies show that while many patients fare well and are leading productive lives, gender dysphoria has been underestimated in the past and that gender counseling as well as sexual counseling should be part of the multi-disciplinary service available to patients with DSD.
  • More emphasis is also needed on strategies to prevent the development of germ cell cancers.
  • [MeSH-minor] Adrenal Hyperplasia, Congenital / pathology. Adrenal Hyperplasia, Congenital / psychology. Adrenal Hyperplasia, Congenital / therapy. Female. Humans. Male. Outcome Assessment (Health Care). Time Factors

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18987501.001).
  • [ISSN] 1661-5433
  • [Journal-full-title] Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology of sex determination and differentiation
  • [ISO-abbreviation] Sex Dev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 109
  •  go-up   go-down


74. Iorgulescu R, Ilie R, Iorgulescu A, Borca V, Dragomirescu C: [Intraabdominal malignant pathology missed at laparoscopic cholecystectomy]. Chirurgia (Bucur); 2005 Mar-Apr;100(2):121-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraabdominal malignant pathology missed at laparoscopic cholecystectomy].
  • [Transliterated title] Patologie malignă abdominală omisă la colecistectomia laparoscopică.
  • Studying the archives of our clinic from January 1995 up to December 2003, we found 15 cases of intraabdominal neoplasia diagnosed in the year that followed laparoscopic cholecystectomy: 7 colorectal cancers, 4 pancreatic cancers, 2 gastric carcinomas, one uterine and one adrenocortical malignancies.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Cholecystectomy, Laparoscopic. Diagnostic Errors
  • [MeSH-minor] Adrenal Cortex Neoplasms / diagnosis. Adult. Aged. Colorectal Neoplasms / diagnosis. Female. Humans. Male. Medical Records. Middle Aged. Pancreatic Neoplasms / diagnosis. Retrospective Studies. Stomach Neoplasms / diagnosis. Uterine Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15957452.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


75. Zacharopoulou C, Nassif J, Allemann P, Dallemagne B, Perretta S, Marescaux J, Wattiez A: Exploration of the retroperitoneum using the transvaginal natural orifice transluminal endoscopic surgery technique. J Minim Invasive Gynecol; 2009 Mar-Apr;16(2):198-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An excellent view of the retroperitoneal space and structures, such as the vascular and lymphatic tissues, the kidney, the adrenal gland, and the ureter, was obtained.

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Minim Invasive Gynecol. 2009 Sep-Oct;16(5):659; author reply 659 [19835818.001]
  • (PMID = 19249708.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Przybylik-Mazurek E, Darczuk A, Huszno B, Budzyński A, Rembiasz K, Gałazka K, Wierzchowski W, Giza A, Jurczak W, Skotnicki AB, Sztuk S, Urbanik A: [Primary adrenal lymphoma in incidentally discovered adrenal tumour]. Przegl Lek; 2006;63(8):701-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adrenal lymphoma in incidentally discovered adrenal tumour].
  • The new imaging techniques used during the last several years: ultrasound, computed tomography and magnetic resonance imaging have improved detection of non-functional adrenal tumours s.c. "incidentaloma".
  • Incidence of adrenal incidentaloma is not very low.
  • In most of cases incidentaloma are benign and gave no clinical signs; however primary adrenal cortex cancer and metastases of different cancers are not uncommon.
  • The primary adrenal lymphoma is an extremely rare disease.
  • Most frequently both adrenal glands are affected and signs of adrenal insufficiency (despite weakness, fever and loss of weight) are present.
  • Hormonal examinations were normal, but the tumour size was indication for surgery treatment.
  • The diagnosis was made by histological examination and adjuvant chemotherapy was administrated.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Adrenal Gland Neoplasms / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / surgery

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17441388.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


77. Wu PP, Kuo SC, Huang WW, Yang JS, Lai KC, Chen HJ, Lin KL, Chiu YJ, Huang LJ, Chung JG: (-)-Epigallocatechin gallate induced apoptosis in human adrenal cancer NCI-H295 cells through caspase-dependent and caspase-independent pathway. Anticancer Res; 2009 Apr;29(4):1435-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (-)-Epigallocatechin gallate induced apoptosis in human adrenal cancer NCI-H295 cells through caspase-dependent and caspase-independent pathway.
  • Nevertheless, there are no reports to date about the molecular mechanisms and signal pathways of EGCG on the induction of apoptosis in human adrenal NCI-H295 cancer cells.
  • The purpose of this study was to investigate the anticancer effect and molecular mechanisms of EGCG on human adrenal NCI-H295 cancer cells.
  • When NCI-H295 cells were treated with 20 microM EGCG, the mitochondrial membrane potential decreased and intracellular free Ca(2+) increased in a time-dependent manner as analysed by flow cytometry.
  • Based on the above findings, it was confirmed that EGCG may be a drug candidate for the treatment of human adrenal cancer in the future.
  • [MeSH-major] Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / pathology. Anticarcinogenic Agents / pharmacology. Apoptosis / drug effects. Caspases / metabolism. Catechin / analogs & derivatives
  • [MeSH-minor] Blotting, Western. Calcium / metabolism. Flow Cytometry. Humans. Membrane Potential, Mitochondrial / drug effects. Protease Inhibitors / pharmacology. Tumor Cells, Cultured


78. Lawnicka H, Kowalewicz-Kulbat M, Sicinska P, Altmann KH, Hofmann T, Stepien H: Resorcylic acid lactone L-783,277 inhibits the growth of the human adrenal cancer cell line H295R in vitro. Int J Immunopathol Pharmacol; 2009 Oct-Dec;22(4):889-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resorcylic acid lactone L-783,277 inhibits the growth of the human adrenal cancer cell line H295R in vitro.
  • However, the role of this compound in the regulation of endocrine-related cancer cell growth and tumor progression remains unknown.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Lactones / pharmacology. Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors. Protein Kinase Inhibitors / pharmacology. Resorcinols / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Cell Cycle / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Humans. Inhibitory Concentration 50

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20074452.001).
  • [ISSN] 0394-6320
  • [Journal-full-title] International journal of immunopathology and pharmacology
  • [ISO-abbreviation] Int J Immunopathol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / L 783277; 0 / Lactones; 0 / Protein Kinase Inhibitors; 0 / Resorcinols; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
  •  go-up   go-down


79. Haleblian GE, Wilson C, Haddad D, Albala DM: Adrenocortical carcinoma: role of laparoscopic surgery in treatment. Expert Rev Anticancer Ther; 2007 Sep;7(9):1295-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adrenocortical carcinoma is a rare disorder with a prevalence of one case per 1.7 million people and a generally poor prognosis.
  • It accounts for 0.02% of all cancer cases and 0.2% of cancer deaths.
  • Within the past three decades, accurate diagnosis, precise radiologic localization, satisfactory preoperative medical management, appropriate anesthesia and refined surgical techniques have come together to render the surgical management of adrenal abnormalities a safe endeavor with predictable outcomes.
  • While there is a general agreement on the suitability of the laparoscopic approach for benign adrenal lesions, controversy remains regarding the use of laparoscopy for suspected adrenal malignancies.
  • This paper provides an overview of adrenal cancer and reviews the literature on laparoscopic adrenalectomy for cancer, including the operative techniques, indications and contraindications.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery. Laparoscopy / methods

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892430.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 28
  •  go-up   go-down


80. Ismail A, Bateman A: Expression of TBX2 promotes anchorage-independent growth and survival in the p53-negative SW13 adrenocortical carcinoma. Cancer Lett; 2009 Jun 18;278(2):230-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The transcriptional regulator TBX2 is genetically amplified in several cancers and has, in addition, important roles in development.
  • This is a cell type-dependent effect as TBX2 overexpression in PANC1 pancreatic cancer cells which are p53-negative has no effect on colony formation or survival after irradiation.
  • Our findings identify TBX2 as a cell type-dependent survival factor under a p53-negative background, and are indicative of a potentially wider role for TBX2 in carcinogenesis than hitherto described.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. T-Box Domain Proteins / physiology. Tumor Suppressor Protein p53 / physiology
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation. Cell Survival / drug effects. Cell Survival / radiation effects. Doxorubicin / pharmacology. Endoplasmic Reticulum / metabolism. Humans. Phosphatidylinositol 3-Kinases / physiology

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19216023.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / T-Box Domain Protein 2; 0 / T-Box Domain Proteins; 0 / Tumor Suppressor Protein p53; 80168379AG / Doxorubicin; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  •  go-up   go-down


81. Lai M, Lü B, Xing X, Xu E, Ren G, Huang Q: Secretagogin, a novel neuroendocrine marker, has a distinct expression pattern from chromogranin A. Virchows Arch; 2006 Oct;449(4):402-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Preliminary data suggest that secretagogin (SCGN), a calcium-binding protein identified from our previous proteomics study of colorectal cancers, is a potentially useful neuroendocrine marker.
  • In this study, we further analyzed SCGN expression in normal and tumor tissues from various organ sites compared with three other conventional neuroendocrine markers [chromogranin A (CgA), neuron specific enolase, and synaptophysin].
  • We found strong SCGN staining in most normal neuroendocrine tissues except in the adrenal cortex.
  • In a subset of neuroendocrine tumors, such as gastric neuroendocrine cancers and typical carcinoid tumors of rectum and ovary, SCGN showed strong staining while CgA expression was often negative.
  • It is intriguing to note that SCGN staining was positive in 26 out of 31 small cell lung cancers, more frequently than the other three markers.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Calcium-Binding Proteins / metabolism. Chromogranin A / metabolism. Neuroendocrine Tumors / metabolism. Neurosecretory Systems / metabolism. Pathology, Surgical / methods

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1267-76 [9777989.001]
  • [Cites] Am J Pathol. 1990 Feb;136(2):375-82 [1689542.001]
  • [Cites] Am J Surg Pathol. 1992 Jun;16(6):561-76 [1376022.001]
  • [Cites] Mod Pathol. 1989 Nov;2(6):652-7 [2587570.001]
  • [Cites] J Endocrinol. 1998 Mar;156(3):469-76 [9582503.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10 ):963-9 [14559978.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:12-5 [15477709.001]
  • [Cites] Eur J Gastroenterol Hepatol. 1995 Jul;7(7):667-74 [8590163.001]
  • [Cites] Cereb Cortex. 2001 Dec;11(12):1161-9 [11709487.001]
  • [Cites] Endocr Relat Cancer. 2004 Mar;11(1):1-18 [15027882.001]
  • [Cites] J Pathol. 1997 May;182(1):13-21 [9227337.001]
  • [Cites] Am J Surg Pathol. 1991 Nov;15(11):1072-7 [1928557.001]
  • [Cites] J Urol. 2001 Sep;166(3):871-5 [11490236.001]
  • [Cites] Histopathology. 2005 Feb;46(2):195-201 [15693892.001]
  • [Cites] J Am Coll Surg. 1994 Aug;179(2):231-48 [8044398.001]
  • [Cites] Diagn Mol Pathol. 1992 Sep;1(3):165-72 [1342962.001]
  • [Cites] N Engl J Med. 2003 Mar 20;348(12):1134-49 [12646671.001]
  • [Cites] Diabetologia. 2004 Feb;47(2):284-99 [14722648.001]
  • [Cites] Proteomics. 2006 May;6(9):2916-23 [16586428.001]
  • [Cites] Neuroendocrinology. 2005;82(2):121-38 [16449819.001]
  • [Cites] Am J Surg Pathol. 1988 Nov;12(11):877-84 [2847571.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24740-51 [10811645.001]
  • [Cites] Virchows Arch. 1997 Jun;430(6):455-60 [9230910.001]
  • [Cites] Pituitary. 2003;6(4):189-202 [15237930.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):140-6 [10697270.001]
  • [Cites] Am J Clin Pathol. 1994 Oct;102(4):406-14 [7524299.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1523-34 [15817359.001]
  • [Cites] Am J Surg Pathol. 1995 Feb;19(2):173-82 [7832277.001]
  • [Cites] Thorax. 1995 Feb;50(2):116-20 [7701447.001]
  • [Cites] Am J Pathol. 1984 Jun;115(3):458-68 [6375394.001]
  • [Cites] Anticancer Res. 2003 Jul-Aug;23(4):3379-96 [12926079.001]
  • (PMID = 16955307.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Chromogranin A; 0 / SCGN protein, human; 0 / Secretagogins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


82. Kozarek RA: The society for gastrointestinal intervention. Are we, as an organization of disparate disciplines, cooperative or competitive? Gut Liver; 2010 Sep;4 Suppl 1:S1-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is the Fourth Annual Meeting of the Society for Gastrointestinal Intervention, a multi-disciplinary group of practitioners committed to a minimally invasive approach to both the diagnosis and treatment of digestive disorders.
  • As a group, the amount of practice devoted to GI disorders is variable (for instance, minimally invasive surgeons may approach the adrenal glands or lung lesions in some institutions and interventional radiologists often sample tissue in multiple areas outside the GI tract, and by virtue of access to the vascular tree, can stent, embolize, or TPA almost any area of the body), as well as inherent differences in our individual abilities to access organs.
  • I have already mentioned that angiographic capabilities allow the interventional radiologist access to virtually every GI organ and those capabilities allow therapeutic options for bleeding, tumor embolization, stenting of stenotic lesions, and formation of intravascular shunts.
  • The same has proven true for many years for colorectal polyps, superficial gastric cancers, and ampullary adenomas that had historically all been treated with major surgical resections.
  • Will this play a bit part and a cooperative technique to expand our therapeutic armamentarium or will it become competitive therapeutically not only for IR but for minimally invasive surgeons?
  • What is the role of TNFerade injection into unresectable pancreatic cancers and the role of absolute alcohol or Taxitol to treat cystic neoplasms of the pancreas?
  • The real issue of competition or cooperation between the disciplines comes when treating patients with unresectable and obstructing GI neoplasms, from my perspective.
  • To my knowledge, although there are studies demonstrating the superiority of SEMS over open or laparoscopic bypass for malignant gastric outlet obstruction insofar as return of gut function, hospitalization time, and resource utilization, there are no studies demonstrating the superiority of one discipline or another in the placement of SEMS.
  • The situation is a bit more complex in pancreaticobiliary malignancy.
  • There are 2 prospective randomized trials (level 1 evidence) that suggest that patients with proximal strictures (Bismuth II-IV) in conjunction with bile duct and gallbladder cancer, respectively, may be more successfully stented percutaneously and certainly it is easier to deliver brachytherapy or PDT under protocol to these patients who have indwelling external drains.
  • In contrast, there are no data, positive or negative, to suggest that PTBD is a preferable treatment for distal biliary malignant obstruction, and in most parts of the world, the endoscopic approach has supplanted the percutaneous one just as metal stents have replaced plastic prostheses to preclude recurrent bouts of stent dysfunction and need for additional ERCP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2003 Mar;35(3):234-8 [12584644.001]
  • [Cites] Endoscopy. 1997 Aug;29(6):570-6 [9342573.001]
  • [Cites] Hepatogastroenterology. 2007 Mar;54(74):503-7 [17523308.001]
  • [Cites] J Am Coll Radiol. 2007 Nov;4(11):816-24 [17964504.001]
  • [Cites] Radiologia. 2007 Nov-Dec;49(6):381-7 [18021665.001]
  • [Cites] World J Gastroenterol. 2008 May 14;14(18):2844-50 [18473408.001]
  • [Cites] J Surg Educ. 2008 Nov-Dec;65(6):418-30 [19059172.001]
  • [Cites] Gastrointest Endosc. 2009 May;69(6):1085-94 [19243764.001]
  • [Cites] Surg Endosc. 2009 Jul;23(7):1512-8 [19343435.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2009;16(3):270-3 [19347662.001]
  • [Cites] J Gastrointest Surg. 2009 Sep;13(9):1733-40 [19412642.001]
  • [Cites] Gastroenterol Clin Biol. 2009 Aug-Sep;33(8-9):758-66 [19683406.001]
  • [Cites] Surg Innov. 2009 Sep;16(3):211-7 [19723692.001]
  • [Cites] Gastrointest Endosc. 2010 Jan;71(1):212-4 [19748611.001]
  • [Cites] J Gastroenterol. 2009;44(12):1195-202 [19763389.001]
  • [Cites] J Gastrointest Surg. 2009 Dec;13(12):2170-5 [19777312.001]
  • [Cites] Surg Endosc. 2010 Apr;24(4):970 [19789919.001]
  • [Cites] Gastrointest Endosc. 2010 Jan;71(1):79-84 [19863956.001]
  • [Cites] Dig Liver Dis. 2010 Jun;42(6):419-24 [19897427.001]
  • [Cites] Surg Endosc. 2010 May;24(5):1080-4 [19911223.001]
  • [Cites] Am J Gastroenterol. 2010 May;105(5):1087-93 [19935785.001]
  • [Cites] World J Gastroenterol. 2009 Dec 21;15(47):5889-97 [20014452.001]
  • [Cites] N Engl J Med. 2010 Jan 14;362(2):129-37 [20071702.001]
  • [Cites] N Engl J Med. 2010 Jan 14;362(2):170-2 [20071708.001]
  • [Cites] Am J Surg. 2010 Feb;199(2):263-5 [20113703.001]
  • [Cites] Gastrointest Endosc. 2010 Feb;71(2):402-6 [20152318.001]
  • [Cites] Surgeon. 2010 Feb;8(1):44-50 [20222402.001]
  • [Cites] J Am Coll Surg. 2010 Apr;210(4):436-40 [20347735.001]
  • [Cites] Endoscopy. 2010 Jun;42(6):496-502 [20419625.001]
  • [Cites] Hepatogastroenterology. 2010 Jan-Feb;57(97):12-7 [20422864.001]
  • [Cites] Endoscopy. 2010 Jul;42(7):571-5 [20432208.001]
  • [Cites] Surg Technol Int. 2010 Apr;19:61-4 [20437346.001]
  • [Cites] Gastrointest Endosc. 2010 May;71(6):1038-45 [20438890.001]
  • [Cites] Gastrointest Endosc. 2004 Dec;60(6):865-74 [15604999.001]
  • (PMID = 21103287.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2989558
  • [Keywords] NOTNLM ; Interventional radiology / Minimally invasive surgery / Therapeutic endoscopy
  •  go-up   go-down


83. Krsek M: [Adrenal cancer]. Vnitr Lek; 2009 Jan;55(1):54-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adrenal cancer].
  • [Transliterated title] Karcinom kůry nadledvin.
  • Adrenal cancer is a rare disease which is often diagnosed at a late stage and usually has a poor prognosis.
  • Further, clinical presentation, diagnostic approach and current treatment options in patients with adrenal cancer are summarized.
  • The multidisciplinary approach as well as centralized care is necessary for successful management of patients with adrenal cancer and for improvement of their poor prognosis.
  • [MeSH-major] Adrenal Cortex Neoplasms

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Vnitr Lek. 2009 Jan;55(1):6 [19227948.001]
  • (PMID = 19227956.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 62
  •  go-up   go-down


84. Delaney HM, Prauner RD, Person DA: Germline p53 mutation in a Micronesian child with adrenocortical carcinoma and subsequent osteosarcoma. J Pediatr Hematol Oncol; 2008 Nov;30(11):803-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Given this child's remarkable history of malignancy, she underwent testing for a genetic mutation that is associated with increased cancer formation.
  • One such cancer syndrome is called Li-Fraumeni syndrome where approximately 70% of patients carry a genetic mutation in the p53 tumor suppressor gene.
  • Patients with LFS are at risk for developing cancers of the breast, soft tissues, brain, bone, adrenal gland, and blood cells.
  • Mutational analysis of our patient did reveal the presence of a germline mutation of the p53 tumor suppressor gene.
  • [MeSH-major] Adrenal Cortex Neoplasms / genetics. Adrenocortical Carcinoma / genetics. Bone Neoplasms / genetics. Germ-Line Mutation / genetics. Neoplasms, Second Primary / genetics. Osteosarcoma / genetics. Tumor Suppressor Protein p53 / genetics


85. Lin MT, Shieh JJ, Chang JH, Chang SW, Chen TC, Hsu WH: Early detection of adrenocortical carcinoma in a child with Li-Fraumeni syndrome. Pediatr Blood Cancer; 2009 Apr;52(4):541-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report an early detection of cancer in a child with Li-Fraumeni syndrome.
  • The proband was a 3-year-old male with a primitive mesenchymal tumor.
  • The younger sister at risk was followed, and an asymptomatic adrenal cortical carcinoma was detected 3 years later.
  • The report highlights the importance of genetic counseling and provides an example of early detection of cancers in childhood LFS carriers.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis. Early Detection of Cancer. Genetic Predisposition to Disease. Li-Fraumeni Syndrome / genetics
  • [MeSH-minor] Child, Preschool. DNA Mutational Analysis. Female. Genetic Counseling. Germ-Line Mutation. Humans. Male. Pedigree. Point Mutation. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Genetic Alliance. consumer health - Li Fraumeni syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 19101993.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


86. Marabelle A, Campagne D, Déchelotte P, Chipponi J, Deméocq F, Kanold J: Focal nodular hyperplasia of the liver in patients previously treated for pediatric neoplastic diseases. J Pediatr Hematol Oncol; 2008 Jul;30(7):546-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY: The discovery of a liver nodule during postcancer follow-up suggests malignancy recurrence.
  • However, patients previously treated for pediatric cancers are at greater risk of developing benign hepatic tumors, raising the problems of getting an accurate noninvasive diagnosis.
  • Radiologic findings and needle-biopsies remained insufficient in 2 cases to rule out metastasis or a potentially threatening tumor.
  • Only surgical resection led to positive diagnosis and prevented complications.
  • [MeSH-major] Adrenal Gland Neoplasms / complications. Focal Nodular Hyperplasia / diagnosis. Kidney Neoplasms / complications. Neuroblastoma / complications. Wilms Tumor / complications
  • [MeSH-minor] Adenoma / diagnosis. Adolescent. Adult. Biopsy, Needle. Bone Marrow Transplantation / adverse effects. Chromosomes, Human, Pair 7. Cicatrix / etiology. Diagnosis, Differential. Female. Graft vs Host Disease / pathology. Humans. Liver / pathology. Liver / radiography. Liver / ultrasonography. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Male. Monosomy. Pancytopenia / complications. Pancytopenia / genetics. Pancytopenia / surgery. Remission Induction


87. Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M, Worden FP: Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer; 2005 Sep;12(3):667-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of patients with adrenal cancer: recommendations of an international consensus conference.
  • Adrenocortical carcinomas are rare, highly malignant tumors that account for only 0.2% of deaths due to cancer.
  • Given the limited number of patients seen in most medical centers with this diagnosis, series usually reported are small and clinical trials not randomized or blinded.
  • In an attempt to answer important questions concerning the management of patients with adrenal cancer, a consensus conference was organized and held at the University of Michigan in Ann Arbor, MI, 11-13 September 2003, with the participation of an international group of physicians who had reported on the largest series of patients with this disease and who had recognized basic and clinical research expertise in adrenal cortical cancer.
  • In addition to setting up guidelines in specific areas of the diagnosis and treatment of adrenal cancer, the conference recommended and initiated the planning of an international prospective trial for treatment of patients with adrenal cancer in stages III and IV.
  • In terms of new therapies, first trials of dendritic cell therapy in human subjects with adrenal cancer have been started, but it is too early to comment on efficacy.
  • There are no clinical gene therapy trials for human adrenal cortical cancer.
  • The adrenals are a preferred target for adenovirus and the results of gene therapy in preclinical studies are promising.
  • In addition, there is evidence that histone deacetylase inhibitors can further enhance the rate of adenoviral infectivity in human adrenal cancer cells.
  • The use of these and other agents in the treatment of adrenal cancer should be hypothesis-driven and based on a thorough analysis of tumor biology.
  • [MeSH-major] Adrenal Gland Neoplasms / therapy
  • [MeSH-minor] Humans. Neoplasm Staging

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172199.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M 01-RR000 42
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Number-of-references] 75
  •  go-up   go-down


88. Chevalier N, Barlier A, Roche C, Mograbi B, Camparo P, Devouassoux-Shisheboran M, Michiels JF, Nebout M, Chevallier D, Benahmed M, Enjalbert A, Fénichel P: RET gene mutations are not involved in the origin of human testicular seminoma. Int J Androl; 2010 Dec;33(6):848-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Testicular germ cell cancers are the most common solid malignancies in young men, but their pathogenesis remains undetermined although some epidemiological data have implicated both environmental and genetic factors.
  • Over-expression of GDNF in adult transgenic mice induces the development of testicular tumours that mimic human seminoma, the most frequent testicular germ cell tumour.
  • Activating mutations of RET were previously reported in several types of cancer, including thyroid, pituitary, adrenal and melanoma cancer.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / genetics. Proto-Oncogene Proteins c-ret / genetics. Seminoma / genetics
  • [MeSH-minor] Animals. Glial Cell Line-Derived Neurotrophic Factor / genetics. Humans. Male. Mice. Testicular Neoplasms / genetics

  • Genetic Alliance. consumer health - Seminoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. International Journal of Andrology © 2010 European Academy of Andrology.
  • (PMID = 20201982.001).
  • [ISSN] 1365-2605
  • [Journal-full-title] International journal of andrology
  • [ISO-abbreviation] Int. J. Androl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glial Cell Line-Derived Neurotrophic Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human
  •  go-up   go-down


89. Geli J, Kiss N, Lanner F, Foukakis T, Natalishvili N, Larsson O, Kogner P, Höög A, Clark GJ, Ekström TJ, Bäckdahl M, Farnebo F, Larsson C: The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma. Endocr Relat Cancer; 2007 Mar;14(1):125-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NORE1A (RASSF5) and RASSF1A are newly described Ras effectors with tumour suppressor functions.
  • Both molecules are frequently inactivated in various cancers.
  • Significantly suppressed NORE1A and RASSF1A mRNA levels were detected in primary tumours compared with normal adrenal medulla (P<0.001).
  • Methylation of the RASSF1A promoter was significantly associated with malignant behaviour (P<0.05).
  • [MeSH-major] Abdominal Neoplasms / genetics. Monomeric GTP-Binding Proteins / genetics. Paraganglioma / genetics. Pheochromocytoma / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Pheochromocytoma.
  • MedlinePlus Health Information. consumer health - Pheochromocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17395981.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / RASSF5 protein, human; 0 / RNA, Messenger; 0 / Sulfites; 0 / Tumor Suppressor Proteins; EC 3.6.5.2 / Monomeric GTP-Binding Proteins; OJ9787WBLU / hydrogen sulfite
  •  go-up   go-down


90. Gau JT, Acharya U, Khan S, Heh V, Mody L, Kao TC: Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr; 2010;10:45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The controls were patients without the discharge diagnosis of pneumonia or acute exacerbation of chronic obstructive pulmonary disease (COPD) (N = 952).
  • Patients with gastric tube feeding, ventilator support, requiring hemodialysis, metastatic diseases or active lung cancers were excluded.
  • CONCLUSION: Our study reaffirmed that the use of inhaled corticosteroids and atypical antipsychotics was both associated with an increased risk for CAP in hospitalized older adults of a rural community.
  • [MeSH-major] Adrenal Cortex Hormones / adverse effects. Antipsychotic Agents / adverse effects. Community-Acquired Infections / chemically induced. Community-Acquired Infections / epidemiology. Pneumonia / chemically induced. Pneumonia / epidemiology

  • MedlinePlus Health Information. consumer health - Pneumonia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2005 Dec 7;294(21):2712-9 [16333006.001]
  • [Cites] Clin Infect Dis. 2004 Dec 1;39(11):1642-50 [15578365.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Jan 15;175(2):144-9 [17053207.001]
  • [Cites] N Engl J Med. 2007 Feb 22;356(8):775-89 [17314337.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(2):CD002991 [17443520.001]
  • [Cites] Arch Intern Med. 2007 May 14;167(9):950-5 [17502537.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Jul 15;176(2):162-6 [17400730.001]
  • [Cites] Int J Tuberc Lung Dis. 2008 Jan;12(1):26-32 [18173873.001]
  • [Cites] J Am Geriatr Soc. 2008 Apr;56(4):661-6 [18266664.001]
  • [Cites] Respir Res. 2008;9:62 [18710575.001]
  • [Cites] Ann Intern Med. 2008 Sep 16;149(6):391-8 [18794558.001]
  • [Cites] Can J Gastroenterol. 2008 Sep;22(9):761-6 [18818790.001]
  • [Cites] Thorax. 2008 Nov;63(11):951-5 [18535116.001]
  • [Cites] JAMA. 2008 Nov 26;300(20):2407-16 [19033591.001]
  • [Cites] Aliment Pharmacol Ther. 2009 Mar 1;29(5):470-80 [19035977.001]
  • [Cites] Arch Intern Med. 2009 Feb 9;169(3):219-29 [19204211.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2009 Apr;18(4):269-75 [19235776.001]
  • [Cites] JAMA. 2009 May 27;301(20):2120-8 [19470989.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2009 Sep;18(9):865-71 [19557730.001]
  • [Cites] Respir Med. 2000 May;94(5):422-7 [10868703.001]
  • [Cites] Respir Med. 2000 Oct;94(10):954-63 [11059948.001]
  • [Cites] Arch Intern Med. 2000 Nov 13;160(20):3082-8 [11074737.001]
  • [Cites] Pharmacopsychiatry. 2004 May;37(3):134-8 [15138897.001]
  • [Cites] JAMA. 2004 Oct 27;292(16):1955-60 [15507580.001]
  • [Cites] Public Health Rep. 1989 Jul-Aug;104(4):350-60 [2502806.001]
  • [Cites] Thorax. 1993 Aug;48(8):785-9 [8211867.001]
  • [Cites] Am J Respir Crit Care Med. 1996 Nov;154(5):1450-5 [8912763.001]
  • [Cites] Arch Intern Med. 1997 Aug 11-25;157(15):1709-18 [9250232.001]
  • [Cites] Eur Respir J. 1999 Feb;13(2):349-55 [10065680.001]
  • [Cites] Chest. 1999 Aug;116(2):375-9 [10453865.001]
  • [Cites] Chest. 2006 Oct;130(4):1096-101 [17035443.001]
  • (PMID = 20604960.001).
  • [ISSN] 1471-2318
  • [Journal-full-title] BMC geriatrics
  • [ISO-abbreviation] BMC Geriatr
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01 AG032298
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antipsychotic Agents; 0 / Proton Pump Inhibitors
  • [Other-IDs] NLM/ PMC2909244
  •  go-up   go-down


91. Simi L, Malentacchi F, Luciani P, Gelmini S, Deledda C, Arvia R, Mannelli M, Peri A, Orlando C: Seladin-1 expression is regulated by promoter methylation in adrenal cancer. BMC Cancer; 2010;10:201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seladin-1 expression is regulated by promoter methylation in adrenal cancer.
  • Adrenal glands show the highest levels of seladin-1 expression, which are significantly reduced in adrenal carcinomas (ACC).
  • Furthermore, to evaluate the presence of an epigenetic regulation also 'in vivo', seladin-1 methylation and its mRNA expression were measured in 9 ACC and in 5 normal adrenal glands.
  • In ACC, methylation density of seladin-1 promoter was higher (2682 +/- 686) than in normal adrenal glands (362 +/- 97; p = 0.02).
  • Seladin-1 mRNA expression in ACC (1452 +/- 196) was significantly lower than in normal adrenal glands (3614 +/- 949; p = 0.01).
  • [MeSH-major] Adrenal Gland Neoplasms / genetics. Carcinoma / genetics. DNA Methylation. Epigenesis, Genetic. Nerve Tissue Proteins / genetics. Oxidoreductases Acting on CH-CH Group Donors / genetics. Promoter Regions, Genetic
  • [MeSH-minor] Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Cell Line, Tumor. DNA Modification Methylases / antagonists & inhibitors. DNA Modification Methylases / metabolism. Enzyme Inhibitors / pharmacology. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Polymerase Chain Reaction. RNA, Messenger / metabolism. Time Factors

  • Genetic Alliance. consumer health - Adrenal Cancer.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci. 2000 Oct 1;20(19):7345-52 [11007892.001]
  • [Cites] Genes Dev. 1995 Jan 1;9(1):97-107 [7828854.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Nov;86(11):5130-7 [11701665.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7457-65 [15569975.001]
  • [Cites] Nature. 2004 Dec 2;432(7017):640-5 [15577914.001]
  • [Cites] J Mol Endocrinol. 2004 Dec;33(3):651-62 [15591025.001]
  • [Cites] Int J Cancer. 2005 Jun 10;115(2):224-30 [15688385.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Jul;63(1):111-5 [15963070.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Nov;90(11):6156-61 [16091489.001]
  • [Cites] EMBO J. 2006 Jan 25;25(2):432-43 [16407971.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5012-20 [16707422.001]
  • [Cites] Eur Urol. 2006 Aug;50(2):290-301 [16455181.001]
  • [Cites] J Endocrinol. 2007 Jan;192(1):53-66 [17210742.001]
  • [Cites] J Neurochem. 2007 Nov;103 Suppl 1:159-70 [17986151.001]
  • [Cites] Mol Cell Biol. 2008 Jan;28(2):539-50 [17984220.001]
  • [Cites] Neurobiol Dis. 2008 Mar;29(3):422-37 [18086530.001]
  • [Cites] Endocrinology. 2008 Jul;149(7):3267-73 [18339707.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1170-6 [11889182.001]
  • [Cites] Neuroscience. 2002;113(2):301-10 [12127087.001]
  • [Cites] FASEB J. 2002 Oct;16(12):1526-36 [12374775.001]
  • [Cites] Ann N Y Acad Sci. 2002 Dec;975:232-46 [12538168.001]
  • [Cites] Clin Biochem. 2003 Feb;36(1):61-5 [12554062.001]
  • [Cites] Int J Oncol. 2003 Nov;23(5):1425-30 [14532986.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):54-69 [14689582.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1332-9 [15001630.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5856-61 [11296263.001]
  • (PMID = 20465827.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 776B62CQ27 / decitabine; EC 1.3.- / Oxidoreductases Acting on CH-CH Group Donors; EC 1.3.1.- / DHCR24 protein, human; EC 2.1.1.- / DNA Modification Methylases; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC2875219
  •  go-up   go-down


92. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Morris C, Xi Y, Howell P, Metge B, Samant RS, Shevde LA, Li W, Eschrich S, Daud A, Ju J, Matta J: The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics; 2008 Apr 28;1:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis.
  • BACKGROUND: The process of malignant transformation, progression and metastasis of melanoma is poorly understood.
  • Gene expression profiling of human cancer has allowed for a unique insight into the genes that are involved in these processes.
  • Thus, we have attempted to utilize this approach through the analysis of a series of primary, non-metastatic cutaneous tumors and metastatic melanoma samples.
  • METHODS: We have utilized gene microarray analysis and a variety of molecular techniques to compare 40 metastatic melanoma (MM) samples, composed of 22 bulky, macroscopic (replaced) lymph node metastases, 16 subcutaneous and 2 distant metastases (adrenal and brain), to 42 primary cutaneous cancers, comprised of 16 melanoma, 11 squamous cell, 15 basal cell skin cancers.
  • A variety of statistical software, including the Affymetrix MAS 5.0 analysis software, was utilized to compare primary cancers to metastatic melanomas.
  • The expression levels of putative oncogenes and tumor suppressor genes were analyzed by semi- and real-time quantitative RT-PCR (qPCR) and Western blot analysis was performed on select genes.
  • We further evaluated primary melanomas of varying Breslow's tumor thickness to determine that the transition in expression occurs at different thicknesses for different genes suggesting that the "transition zone" represents a critical time for the emergence of the metastatic phenotype.
  • Several putative tumor oncogenes (SPP-1, MITF, CITED-1, GDF-15, c-Met, HOX loci) and suppressor genes (PITX-1, CST-6, PDGFRL, DSC-3, POU2F3, CLCA2, ST7L), were identified and validated by quantitative PCR as changing expression during this transition period.


93. Roman S: Adrenocortical carcinoma. Curr Opin Oncol; 2006 Jan;18(1):36-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Adrenocortical carcinoma is a rare malignancy, accounting for 0.02% of all annual cancers reported.
  • Given the generally advanced stage at diagnosis, the overall 5-year survival remains poor, varying between 20 and 45%.
  • RECENT FINDINGS: Recent studies focusing on the tumorigenesis of adrenocortical carcinoma have focused on onco-developmental genes present in the fetal adrenal cortex, as well as local adrenal paracrine and autocrine effects of cellular peptides.
  • SUMMARY: Pre-operative diagnostic advances in positron emission scanning are emerging as promising modalities for confirmation of malignancy of indeterminate adrenal masses.
  • [MeSH-major] Adrenal Cortex Neoplasms. Adrenocortical Carcinoma

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOTANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357562.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Vascular Endothelial Growth Factor A; 104625-48-1 / Activins; 57285-09-3 / Inhibins; 78E4J5IB5J / Mitotane
  • [Number-of-references] 38
  •  go-up   go-down


94. Zhang C, Mattern J, Haferkamp A, Pfitzenmaier J, Hohenfellner M, Rittgen W, Edler L, Debatin KM, Groene E, Herr I: Corticosteroid-induced chemotherapy resistance in urological cancers. Cancer Biol Ther; 2006 Jan;5(1):59-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corticosteroid-induced chemotherapy resistance in urological cancers.
  • PURPOSE: Glucocorticoids such as dexamethasone are widely used for medication of urological diseases, e.g., as cotreatment of advanced prostate cancer, to improve appetite, weight loss, fatigue, relieve bone pain, diminish ureteric obstruction, to reduce the production of adrenal androgens, as an antiemetic in patients undergoing chemo- and/or radiotherapy together with serving as "standard" therapy arm in randomized studies.
  • While the potent pro-apoptotic properties and the supportive effects of glucocorticoids to tumor therapy in lymphoid cells are well studied, the impact to growth of prostate and other urological carcinomas is unknown.
  • METHODS: We isolated cells from surgical resections of 21 prostate tumors and measured apoptosis and viability in these primary cells and 17 established cell lines from human prostate, bladder, renal cell and testicular carcinomas.
  • No difference in dexamethasone-mediated protection was found in normal, benign and malignant prostate tumors.
  • CONCLUSIONS: These data show for the first time that dexamethasone induced therapy resistance in urological carcinomas is not the exception but a more common phenomenon and implicate that glucocorticoids may have two faces in cancer therapy, a beneficial and a dangerous one.
  • [MeSH-major] Adrenal Cortex Hormones / adverse effects. Dexamethasone / adverse effects. Drug Resistance, Neoplasm / drug effects. Urologic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16294015.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


96. Ingudomnukul E, Baron-Cohen S, Wheelwright S, Knickmeyer R: Elevated rates of testosterone-related disorders in women with autism spectrum conditions. Horm Behav; 2007 May;51(5):597-604
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The androgen theory of autism proposes that autism spectrum conditions (ASC) are in part due to elevated fetal testosterone (FT) levels, which are positively correlated with a number of autistic traits and inversely correlated with social development and empathy.
  • A medical questionnaire was completed by n=54 women with ASC, n=74 mothers of children with ASC, and n=183 mothers of typically developing children to test whether women with ASC have an increased rate of testosterone-related medical conditions, and to see whether mothers of children with ASC show similar abnormalities, as part of the 'broader autism phenotype'.
  • Compared to controls, significantly more women with ASC reported (a) hirsutism, (b) bisexuality or asexuality, (c) irregular menstrual cycle, (d) dysmenorrhea, (e) polycystic ovary syndrome, (f) severe acne, (g) epilepsy, (h) tomboyism, and (i) family history of ovarian, uterine, and prostate cancers, tumors, or growths.
  • Compared to controls, significantly more mothers of ASC children reported (a) severe acne, (b) breast and uterine cancers, tumors, or growths, and (c) family history of ovarian and uterine cancers, tumors, or growths.
  • [MeSH-major] Adrenal Hyperplasia, Congenital / complications. Autistic Disorder / complications. Epilepsy / complications. Menstruation Disturbances / complications. Polycystic Ovary Syndrome / complications. Testosterone / blood
  • [MeSH-minor] Acne Vulgaris / blood. Acne Vulgaris / complications. Adult. Case-Control Studies. Female. Gender Identity. Hirsutism / complications. Humans. Middle Aged. Mothers. Reference Values. Risk Factors. Sexuality / physiology. Urogenital Neoplasms / blood. Urogenital Neoplasms / complications


97. Roznovanu SL, Amălinci C, Rădulescu D: Molecular mechanisms in hormone-resistant prostate cancer. Rev Med Chir Soc Med Nat Iasi; 2005 Jul-Sep;109(3)